Document:

Exhibit
10.1 

 

Execution
Version  

 

EXCHANGE
AGREEMENT

 

This
EXCHANGE AGREEMENT (this “Agreement”) is made as of November 10, 2017, by and among TheStreet, Inc., a Delaware
corporation (the “Company”), TCV VI, L.P., a Delaware limited partnership (“TCV VI”), and
TCV Member Fund, L.P., a Cayman Islands exempted limited partnership (“TCV Member Fund” and, together with
TCV VI, the “TCV Holders”). The Company and the TCV Holders are referred to herein individually as a “Party”
and collectively as the “Parties.” Capitalized terms used but not otherwise defined herein shall have the respective
meanings ascribed to such terms in the Investor Rights Agreement, dated as of November 15, 2007, by and among the Company and
the TCV Holders (the “Investor Rights Agreement”) and the Certificate of Designation, Preferences and Rights
of the Series B Preferred Stock of the Company dated as of November 15, 2007 (the “Certificate of Designation”),
as applicable.

 

RECITALS

 

WHEREAS,
as of the date hereof, (i) TCV VI is the record holder of 5,455.95095 shares of Series B convertible preferred stock, par value
$0.01 per share, of the Company (the “Series B Preferred Stock”) and (ii) TCV Member Fund is the record holder
of 44.04905 shares of Series B Preferred Stock;

 

WHEREAS,
the terms of the Series B Preferred Stock and the rights, preferences and privileges attached thereto are set forth in the Certificate
of Designation;

 

WHEREAS,
the Company and the TCV Holders desire to exchange all of the shares of Series B Preferred Stock held by the TCV Holders for an
aggregate of (i) 6,000,000 shares of common stock, par value $0.01 per share, of the Company (the “Common Stock”)
newly issued by the Company (the “Stock Consideration”) and (ii) an amount in cash equal to $20,000,000 (the
“Cash Consideration”), and agree to certain other matters as set forth herein;

 

WHEREAS,
the board of directors of the Company (the “Board”), having determined that this Agreement and the transactions
contemplated hereby are being entered into by the Parties on arm’s-length terms and are advisable, fair to and in the best
interests of the Company, has, at a duly held meeting of the board, authorized and approved this Agreement and the transactions
contemplated hereby;

 

WHEREAS,
concurrently with the consummation of the transactions contemplated hereby, the Company proposes to issue and sell capital stock
of the Company to investors (the “Investors”) for cash in a private placement transaction (the “Concurrent
Private Placement”) pursuant to a securities purchase agreement (the “Private Placement Agreement”);
and

 

WHEREAS,
such Concurrent Private Placement shall occur concurrently with, and be conditioned on, the consummation of the transactions contemplated
hereby.

 

     

     

    

 

NOW,
THEREFORE, in consideration of the foregoing, of the mutual
representations, warranties, covenants and agreements herein contained and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

 

Article
I

TRANSACTIONS

 

1.1         Exchange.

 

(a)        Subject
to and upon the terms and conditions of this Agreement, on the Closing Date, in exchange for the consideration set forth in Section
1.2, and upon delivery by the TCV Holders of the certificate or certificates representing each such TCV Holder’s shares
of Series B Preferred Stock, duly endorsed for transfer to the Company or accompanied by a duly executed stock power in favor
of the Company, the Company shall (i) issue and cause to be delivered book-entry shares representing the Stock Consideration to
the TCV Holders and (ii) pay to the TCV Holders the Cash Consideration. 

 

(b)       Upon
completion of the transactions contemplated hereby, all of the Series B Preferred Stock shall be cancelled and shall cease to
exist and no longer be outstanding and the Company shall promptly
file a Certificate of Elimination of such Series B Preferred Stock pursuant to Section 151 of the General Corporation Law of the
State of Delaware.

 

1.2         Consideration.
Subject to and upon the terms and conditions of this Agreement,
on the Closing Date, in consideration for the exchange of all of the Series B Preferred Stock held by the TCV Holders, the aggregate
consideration payable to the TCV Holders in respect of such exchange shall consist of (i) the Cash Consideration plus (ii)
the Stock Consideration. The Cash Consideration shall be paid, on the Closing Date, by wire transfer of immediately available
funds to one or more accounts designated by the TCV Holders in writing. The Stock Consideration shall be satisfied by the issuance,
on the Closing Date, to the TCV Holders of that number of shares of Common Stock comprising such Stock Consideration appearing
opposite each TCV Holder’s name on Exhibit A attached hereto and the delivery of book-entry shares representing such
shares of Common Stock to the TCV Holders.

 

1.3         The
Closing.

 

(a)          The
consummation of the transactions contemplated by this Agreement, and the performance by the Parties of their respective related
agreements, covenants and obligations hereunder (collectively, the “Closing”) will take place at the offices
of Orrick, Herrington & Sutcliffe LLP at 405 Howard Street, San Francisco, California, at 10:00 a.m., New York time, on the
date hereof (or in such other manner or on such other date or time as the Parties mutually agree) after notification of satisfaction
(or waiver) of the conditions to the Closing set forth in clauses (b) and (c) below.

 

(b)          The
obligations of the Company to the TCV Holders hereunder are subject to the satisfaction of each of the following conditions, provided
that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion
by providing the TCV Holders with prior written notice thereof:

 

(i)       Each
TCV Holder shall have executed and delivered this Agreement to the Company; and

 

    2 

     

    

 

(ii)      Each
TCV Holder shall have delivered the certificate or certificates
representing such TCV Holder’s shares of Series B Preferred Stock, duly endorsed for transfer to the Company or accompanied
by a duly executed stock power in favor of the Company.

 

(c)          The
obligations of each TCV Holder to the Company hereunder are subject to the satisfaction of each of the following conditions, provided
that these conditions are for the TCV Holders’ sole benefit and may be waived by the TCV Holders at any time in their sole
discretion by providing the Company with prior written notice thereof:

 

(i)       The
Company shall have executed and delivered this Agreement to the TCV Holders;

 

(ii)      The
Company shall have issued and caused to be delivered book-entry
shares representing the Stock Consideration to the TCV Holders;

 

(iii)     The
TCV Holders shall have received from the Company the Cash Consideration; and

 

(iv)     The
Company shall have consummated the Concurrent Private Placement on the terms set forth in the Private Placement Investment Documents.

 

(d)       Except
as otherwise provided in this Agreement, all actions to be taken and all documents to be executed and delivered at the Closing
shall be deemed to have been taken, delivered and executed simultaneously, and no action shall be deemed taken nor any documents
deemed executed or delivered until all have been taken, delivered and executed.

 

 

Article
II

REPRESENTATIONS AND WARRANTIES OF the TCV Holders

 

As
an inducement to the Company to enter into and perform this Agreement, each of the TCV Holders, severally and not jointly, hereby
makes the following representations and warranties to the Company as of the date hereof:

 

2.1         Organization
and Power. Such TCV Holder is a limited partnership duly formed, validly existing and in good standing under the laws of the
jurisdiction of its formation. Such TCV Holder has all requisite limited partnership power and authority to execute and deliver
this Agreement and each other agreement, document, instrument or certificate contemplated by this Agreement to which it is a party,
to perform its obligations hereunder and to consummate the transactions contemplated hereby

 

2.2         Authorization,
etc. All limited partnership action on the part of such TCV Holder necessary for the authorization, execution, delivery and
performance by such TCV Holder of this Agreement, and the consummation of the transactions contemplated hereby, has been taken.
This Agreement has been duly and validly executed by such TCV Holder, and, upon delivery hereof by such TCV Holder, will constitute
a valid and binding obligation of such TCV Holder enforceable against such TCV Holder in accordance with its terms, except as
such enforceability may be limited by applicable laws relating to bankruptcy, insolvency, reorganization, moratorium or other
similar legal requirement relating to or affecting creditors’ rights generally and except as such enforceability is subject
to general principles of equity (regardless of whether enforceability is considered in a proceeding in equity or at law).

 

    3 

     

    

  

2.3         Non-Contravention;
Approvals; Actions.

 

(a)       The
authorization, execution, delivery and performance by such TCV Holder of this Agreement, and the consummation by such TCV Holder
of the transactions contemplated hereby, do not and will not: (i) violate or result in the breach of any provision of the certificate
of limited partnership and limited partnership agreement of such TCV Holder; or (ii) with such exceptions that, individually or
in the aggregate, are not reasonably likely to have a material and adverse effect on its ability to perform its obligations under
this Agreement, whether after the giving of notice or the lapse of time or both: (x) violate any provision of, constitute a breach
of, or default under, or result in or permit the cancellation, termination or acceleration of any material contract to which such
TCV Holder is a party; or (y) violate any provision of, constitute a breach of, or default under, any applicable law.

 

(b)       No
consent, waiver, approval, authorization, order or permit of, or declaration, filing or registration with, or notification to,
any governmental authority or other third party is required to be made or obtained by such TCV Holder in connection with the authorization,
execution, delivery and performance by such TCV Holder of this Agreement, and the consummation by the Company of the transactions
contemplated hereby, except (i) applicable filing requirements under federal or state securities or “blue sky” Laws,
and (ii) where the failure to obtain such consent, approval, authorization or action, or to make such filing or notification would
not, when taken together with all other such failures by such TCV Holder, reasonably be expected to have a material and adverse
effect on the ability of such TCV Holder to perform its obligations under this Agreement or consummate the transactions contemplated
by this Agreement.

 

(c)       There
are no claims, actions, suits, proceedings or investigation pending or, to the knowledge of such TCV Holder, threatened against
such TCV Holder, any of the assets or properties of such TCV Holder, or any of the directors and officers of such TCV Holder in
their capacity as directors or officers that would reasonably be expected to have a material and adverse effect on the ability
of such TCV Holder to perform its obligations under this Agreement or consummate the transactions contemplated by this Agreement.

 

2.4         No
Encumbrances. Except pursuant to the Investor Rights Agreement and the
Securities Purchase Agreement, dated as of November 15, 2007, by and among the Company and the TCV Holders (the “Securities
Purchase Agreement”), such TCV Holder owns and holds, beneficially and of record, the entire right, title, and interest
in and to such TCV Holder’s shares of Series B Preferred Stock free and clear of all rights and Encumbrances (as defined
below), and such TCV Holder has full power and authority to transfer and dispose of such shares of Series B Preferred Stock free
and clear of any right or Encumbrance. Other than the transactions contemplated by this Agreement, there is no outstanding agreement
or other right of any person to acquire all or any of the Series B Preferred Stock from such TCV Holders. “Encumbrances”
shall mean any security or other property interest or right, claim, lien, pledge, option, charge, security interest, contingent
or conditional sale, or other title claim or retention agreement, interest or other right or claim of third parties, whether perfected
or not perfected, voluntarily incurred or arising by operation of law, and including any agreement (other than this Agreement)
to grant or submit to any of the foregoing in the future.

 

    4 

     

    

 

2.5         Investment
Representations.

 

(a)       Such
TCV Holder understands and hereby acknowledges that it is aware that the Stock Consideration has not been registered under the
Securities Act of 1933, as amended (the “Securities Act”), or any similar state securities laws.

 

(b)       Such
TCV Holder is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D promulgated under the
Securities Act. Such TCV Holder is acquiring the Stock Consideration for its own account and not with a view to, or for sale in
connection with, any distribution thereof in violation of federal or state securities laws. By reason of its business or financial
experience, such TCV Holder has the capacity to protect its own interest in connection with the transactions contemplated hereunder.

 

(c)       Such
TCV Holder acknowledges that (i) it has conducted its own investigation of the Company and the terms of the Stock Consideration,
(ii) it has had access to the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”)
and to such financial and other information as it deems necessary to make its decision to acquire the Converted Shares and the
Stock Consideration, and (iii) has been offered the opportunity to conduct such review and analysis of the business, assets, condition,
operations and prospects of the Company and to ask questions of the Company and received answers thereto, each as it deemed necessary
in connection with the decision to acquire the Converted Shares and the Stock Consideration. Such TCV Holder further acknowledges
that it has had such opportunity to consult with its own counsel, financial and tax advisors and other professional advisers as
it believes is sufficient for purposes of the acquisition of the Stock Consideration.

 

(d)       The
foregoing, however, does not limit or modify the representations and warranties of the Company in Article III of this Agreement
or the right of such TCV Holder to rely thereon. Such TCV Holder further understands and acknowledges that the representations
and warranties contained in this Article II may be relied upon by the Company as the basis, in part, for the exemption
of the Stock Consideration from the registration requirements under all such federal and state laws. Except for the representations
and warranties contained in Article III of this Agreement, such TCV Holder acknowledges that neither the Company nor any
person on behalf of the Company makes, and such TCV Holder has not relied upon, any other express or implied representation or
warranty with respect to the Company or with respect to any other information provided to such TCV Holder in connection with the
transactions contemplated by this Agreement.

 

    5 

     

    

 

Article
III

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

As
an inducement to the TCV Holders to enter into and perform this Agreement, the Company hereby makes the following representations
and warranties to the TCV Holders that, except as set forth in the SEC Filings where specifically referenced or on the corresponding
sections of the schedules delivered herewith (collectively, the “Disclosure Schedules”):

 

3.1         Organization
and Power. Each of the Company and its Subsidiaries is duly incorporated or otherwise organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation or organization (to the extent the concept of good standing is
recognized in the relevant jurisdiction) and has all requisite power and authority to carry on its business as now conducted and
to own or lease its properties. The Company has all requisite corporate power and authority to execute and deliver this Agreement
and each other agreement, document, instrument or certificate contemplated by this Agreement to which it is a party, to perform
its obligations hereunder and to consummate the transactions contemplated hereby. Each of the Company and its Subsidiaries is
duly qualified to do business as a foreign corporation or other entity and is in good standing in each jurisdiction (to the extent
the concept of good standing is recognized in the relevant jurisdiction) in which the conduct of its business or its ownership
or leasing of property makes such qualification or leasing necessary unless the failure to be in good standing or so qualify has
not had and could not reasonably be expected to have a Material Adverse Effect. The Company’s Subsidiaries are listed on
Schedule 3.1 hereto. 

 

3.2         Authorization,
etc. All corporate action on the part of the Company necessary for the authorization, execution, delivery and performance
by the Company of this Agreement, and the consummation of the transactions contemplated hereby, has been taken. This Agreement
has been duly and validly executed by the Company, and, upon delivery hereof by the Company, will constitute a valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited
by applicable laws relating to bankruptcy, insolvency, reorganization, moratorium or other similar legal requirement relating
to or affecting creditors’ rights generally and except as such enforceability is subject to general principles of equity
(regardless of whether enforceability is considered in a proceeding in equity or at law). Assuming the accuracy of the representations
and warranties of the TCV Holders set forth in Section 2.5, the offer and sale of the Stock Consideration pursuant to this
Agreement will be exempt from the registration requirements of the Securities Act.

 

3.3         Non-Contravention;
Approvals; Litigation; Compliance.

 

(a)       The
authorization, execution, delivery and performance by the Company of this Agreement, and the consummation by the Company of the
transactions contemplated hereby, do not and will not: (i) violate or result in the breach of any provision of the certificate
of incorporation and bylaws of the Company; (ii) require any approval by the stockholders of the Company, including any approval
by the shareholders of the Company under Nasdaq Rule 5635; or (iii) with such exceptions that, individually or in the aggregate,
are not reasonably likely to have a material and adverse effect on its ability to perform its obligations under this Agreement,
whether after the giving of notice or the lapse of time or both: (x) violate any provision of, constitute a breach of, or default
under, or result in or permit the cancellation, termination or acceleration of any material judgment, order, writ, decree or contract
required to be filed as an exhibit to one of the Company’s filings with the SEC; or (y) violate any provision of, constitute
a breach of, or default under, any applicable law.

 

    6 

     

    

 

(b)       No
consent, waiver, approval, authorization, order or permit of, or declaration, filing or registration with, or notification to,
any governmental authority or other third party is required to be made or obtained by the Company in connection with the authorization,
execution, delivery and performance by the Company of this Agreement, and the consummation by the Company of the transactions
contemplated hereby, except (i) applicable filing requirements under federal or state securities or “blue sky” Laws,
and (ii) where the failure to obtain such consent, approval, authorization or action, or to make such filing or notification would
not, when taken together with all other such failures by the Company, reasonably be expected to have a material and adverse effect
on the ability of the Company to perform its obligations under this Agreement or consummate the transactions contemplated by this
Agreement.

 

(c)       There
are no claims, actions, suits, proceedings or investigation pending or, to the knowledge of the Company, threatened against the
Company, any of the assets or properties of the Company, or any of the directors and officers of the Company in their capacity
as directors or officers that would reasonably be expected to have a material and adverse effect on the ability of the Company
to perform its obligations under this Agreement or consummate the transactions contemplated by this Agreement.

 

(d)       The
Company has not, in connection with the transactions contemplated by this Agreement, engaged in: (a) any form of general solicitation
or general advertising (as those terms are used within the meaning of Rule 502(c) promulgated under the Securities Act); (b) any
action involving a “public offering” within the meaning of Section 4(a)(2) of the Securities Act; or (c) any action
that would require the registration under the Securities Act of the offering and sale of the Stock Consideration pursuant to this
Agreement. As used herein, the terms “offer” and “sale” have the meanings specified in Section 2(a)(3)
of the Securities Act.

 

(e)       The
consummation of the transactions contemplated hereby complies with Section 160 of the General Corporation Law of the State of
Delaware, the capital of the Company is not currently impaired, and the consummation of the transactions contemplated by this
Agreement will not cause any impairment of the capital of the Company. 

 

3.4         Authorized
Stock. All of the shares of the Stock Consideration have been duly authorized and, when delivered to the TCV Holders upon
the consummation of the transactions contemplated hereby, will be validly issued and fully paid and nonassessable and will not
be subject to any preemptive right or any restrictions on transfer under applicable law or any contract to which the Company is
a party, other than those under applicable state and federal securities and antitakeover laws and the Investor Rights Agreement.
When issued in accordance with the terms hereof, the Stock Consideration will be free and clear of all Encumbrances imposed by
or through the Company, except for restrictions imposed by federal or state securities or “blue sky” laws and except
for those imposed pursuant to this Agreement or the Investor Rights Agreement.

 

3.5         Capitalization.

 

(a)       The
authorized capital stock of the Company (immediately prior to the Closing) consists of 100,000,000 shares of Common Stock and
10,000,000 shares of preferred stock, par value $0.01 per share (“Preferred Stock”).

 

    7 

     

    

 

(b)       As
of the date hereof, the issued and outstanding capital stock of the Company consists of 43,411,044 shares of Common Stock issued,
of which 35,877,562 shares are outstanding and 7,533,482 shares are held as treasury stock, and 5,500 shares of Series B Preferred
Stock. There are no other outstanding shares of Preferred Stock. In addition, options to purchase an aggregate of 5,383,261 shares
of Common Stock have been granted and are unexercised under the Stock Plans, and unvested restricted stock units (or RSUs) for
an aggregate of 763,067 shares have been granted under the Stock Plans.

 

(c)       Except
as provided in this Agreement and the Private Placement Agreement: (i) no subscription, warrant, option, convertible security
or other right issued by the Company to purchase or acquire any shares of capital stock of the Company is authorized or outstanding;
(ii) except as set forth on Schedule 3.5(c)(ii), there is not any commitment of the Company to issue any subscription,
warrant, option, convertible security or other such right or to issue or distribute to holders of any shares of its capital stock
any evidences of indebtedness or assets of the Company; (iii) the Company has no obligation to purchase, redeem or otherwise acquire
any shares of its capital stock or any interest therein or to pay any dividend or make any other distribution in respect thereof;
and (iv) there are no agreements between the Company and any holder of its capital stock relating to the acquisition, disposition
or voting of the capital stock of the Company. No person or entity is entitled to any preemptive right granted by the Company
with respect to the issuance of any capital stock of the Company. Except as provided in the Investor Rights Agreement and the
registration rights agreement entered into in connection with the consummation of the transactions contemplated by the Private
Placement Agreement (the “New Registration Rights Agreement”), no person or entity has been granted rights
by the Company with respect to the registration of any capital stock of the Company under the Securities Act.

 

3.6         Private
Placement Agreement. True, correct and complete copies of the Private Placement Agreement and the New Registration Rights
Agreement, each dated as of the date hereof, and any other agreements or arrangements entered into between or among the Company
and the Investors in connection with or related to the Concurrent Private Placement (all such agreements, the “Private
Placement Investment Documents”), have been delivered to the TCV Holders.

 

3.7         Delivery
of SEC Filings; Business. The Company has made available to the TCV Holders through the SEC’s EDGAR system, true and
complete copies of the Company’s reports, schedules, forms, statements and other documents required to be filed by it with
the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
during the two (2) years prior to the date hereof (collectively with all amendments, exhibits, financial statements, notes and
schedules thereto, the “SEC Filings”). The SEC Filings are the only filings required of the Company pursuant
to the Exchange Act for such period. The Company and its Subsidiaries are engaged in all material respects only in the business
described in the SEC Filings.

 

    8 

     

    

 

3.8         No
Material Adverse Change. Since December 31, 2016, except for the transactions contemplated hereby and by the Private Placement
Investment Documents, or as identified and described on Schedule 3.8, there has not been:

 

(i)       any
change in the consolidated assets, liabilities, financial condition or operating results of the Company from that reflected in
the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, except
for changes in the ordinary course of business which have not had and would not reasonably be expected to have a Material Adverse
Effect, individually or in the aggregate;

 

(ii)      any
declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the
Company, or any redemption or repurchase of any securities of the Company;

 

(iii)     any
material damage, destruction or loss, whether or not covered by insurance to any assets or properties of the Company or its Subsidiaries;

 

(iv)     any
waiver, not in the ordinary course of business, by the Company or any Subsidiary of a material right or of a material debt owed
to it;

 

(v)      any
satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company or a Subsidiary, except
in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results
or business of the Company and its Subsidiaries taken as a whole (as such business is presently conducted and as it is proposed
to be conducted);

 

(vi)     any
change or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to any Material Contract
or arrangement by which the Company or any Subsidiary is bound or to which any of their respective assets or properties is subject;

 

(vii)    any
material labor difficulties or labor union organizing activities with respect to employees of the Company or any Subsidiary;

 

(viii)   any
material transaction entered into by the Company or a Subsidiary other than in the ordinary course of business;

 

(ix)      the
loss of the services of any key employee, or material change in the composition or duties of the senior management of the Company
or any Subsidiary;

 

(x)       the
loss, to the Company’s Knowledge, threatened loss of any customer which has had or could reasonably be expected to have
a Material Adverse Effect; or

 

(xi)     any
other event or condition of any character that has had or could reasonably be expected to have a Material Adverse Effect.

 

    9 

     

    

 

3.9         SEC
Filings; Financial Information; S-3 Eligibility.

 

(a)       At
the time of filing thereof, the SEC Filings complied as to form in all material respects with the requirements of the Exchange
Act and, as of their respective dates, did not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under
which they were made, not misleading. To the Company’s Knowledge, the written information furnished by or on behalf of the
Company to any of the TCV Holders prior to the date hereof in connection with the transactions contemplated hereby which is not
included in the SEC Filings (including, without limitation, information referred to in Section 2.5(c) of this Agreement
or in the Disclosure Schedules to this Agreement), taken as a whole, does not contain, as of the date furnished, any untrue statement
of a material fact or omits to state any material fact necessary in order to make the statements therein not misleading, in the
light of the circumstance under which they are or were made; provided that with respect to projections, forecasts, estimates,
budgets and other forward-looking statements and information that were prepared by the Company, the Company only represents that
such projections, forecasts, estimates, budgets and other forward-looking information were prepared in good faith upon assumptions
believed by the Company to be reasonable at the time made. 

 

(b)       The
financial statements included in each SEC Filing comply in all material respects with applicable accounting requirements and the
rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent
restatement) and present fairly, in all material respects, the consolidated financial position of the Company as of the dates
shown and its consolidated results of operations and cash flows for the periods shown, and such financial statements have been
prepared in conformity with United States generally accepted accounting principles applied on a consistent basis (“GAAP”)
(except as may be disclosed therein or in the notes thereto, and, in the case of quarterly financial statements, except for normal
year-end audit adjustments and as otherwise as permitted by Form 10-Q under the Exchange Act).

 

(c)       The
Company satisfies the “registrant requirements” for use of Form S-3 set forth in General Instruction I.A to Form S-3
promulgated by the SEC.

 

3.10       Tax
Matters. The Company and each of its Subsidiaries has filed all tax returns required to be filed by the Company or such Subsidiary
with all appropriate governmental agencies within the applicable periods for such filings (with due regard to any extension) and
has paid all taxes required to be paid, except for any such failures to file or pay that would not individually or in the aggregate
have a Material Adverse Effect. No material deficiencies for any tax are currently assessed against the Company or any of its
Subsidiaries, and no tax returns of the Company or any of its Subsidiaries have been audited during the last three years, and,
there is no such audit pending or, to the knowledge of the Company, contemplated. There is no outstanding claim by an authority
in a jurisdiction where the Company does not file tax returns that it is or may be subject to the imposition of any material tax
by that jurisdiction.

 

3.11       Title
to Properties. The Company and its Subsidiaries do not own any real property; except as disclosed in the SEC Filings, the
Company and each Subsidiary has good and marketable title to all personal property owned by it, in each case free from liens,
encumbrances and defects that would materially affect the value thereof or materially interfere with the use made or currently
planned to be made thereof by them; and except as disclosed in the SEC Filings, the Company and each Subsidiary holds any leased
real or personal property under valid and enforceable leases with no exceptions that would materially interfere with the use made
or currently planned to be made thereof by them.

 

    10 

     

    

 

3.12       Certificates,
Authorities and Permits. The Company and each Subsidiary possess adequate certificates, authorities or permits issued by appropriate
governmental agencies or bodies necessary to conduct the business now operated by it, except where such failure has not had and
would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate, and neither the Company
nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate,
authority or permit that, if determined adversely to the Company or such Subsidiary, would reasonably be expected to have a Material
Adverse Effect, individually or in the aggregate.

 

3.13       Labor
Matters. Except as described on Schedule 3.13, the Company has described in, or filed as an exhibit to, the SEC Filings
filed prior to the date of this Agreement all of the following types of documents, agreements, plans or arrangements that are
required by federal securities laws to be described in, or filed as an exhibit to, the SEC Filings: employment agreements, consulting
agreements, deferred compensation, pension or retirement agreements or arrangements (including all “employee pension benefit
plans” as defined in Section 3(2) of ERISA, bonus, incentive or profit-sharing plans or arrangements, or labor or collective
bargaining agreements in effect by the Company and its Subsidiaries) (the “ERISA Documents”). Except for any
compliance failures that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect,
(a) the Company and its Subsidiaries are in compliance in all respects with all applicable laws and regulations relating to labor,
employment, fair employment practices, terms and conditions of employment, and wages and hours, and with the terms of the ERISA
Documents; and (b) each such ERISA Document is in compliance in all respects with all applicable requirements of ERISA. To the
Company’s Knowledge, none of the Company’s or its Subsidiaries’ employees are obligated under any contract (including
licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court
or administrative agency, that would interfere with the use of his or her employment obligations to the Company or its Subsidiaries
or that would conflict with the Company’s and its Subsidiaries’ business as now conducted or proposed to be conducted,
except for such contracts and other agreements, judgments, decrees and orders that would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. 

 

3.14       Intellectual
Property. All Intellectual Property Rights purported to be owned by the Company or any of its Subsidiaries that were developed,
worked on or otherwise held by any employee, officer, consultant or otherwise are owned free and clear by the Company or one of
its Subsidiaries (as the case may be) by operation of law or have been validly assigned to the Company one of its Subsidiaries
(as the case may be) other than those Intellectual Property Rights where the failure to own or assign such rights would not, individually
or in its aggregate be reasonably likely to have a Material Adverse Effect. The Intellectual Property Rights are sufficient in
all material respects to carry on the business of the Company and each of its Subsidiaries as presently conducted and as proposed
to be conducted. To the Knowledge of the Company, with such exceptions as are not, individually or in the aggregate reasonably
likely to have a Material Adverse Effect, the Intellectual Property Rights purported to be owned by the Company or any of its
Subsidiaries do not infringe the intellectual property rights of any third party. To the Knowledge of the Company, the conduct
of the Company’s and its Subsidiaries’ businesses as currently conducted does not infringe or otherwise impair or
conflict with (collectively, “Infringe”) any Intellectual Property Rights of any third party or any confidentiality
obligation owed to a third party, and, to the Company’s Knowledge, the Intellectual Property Rights and Confidential Information
of the Company and its Subsidiaries which are necessary for the conduct of Company’s and each of its Subsidiaries’
respective businesses as currently conducted or as currently proposed to be conducted are not being Infringed by any third party.
There is no litigation or order pending or outstanding or, to the Company’s Knowledge, threatened, that seeks to limit or
challenge or that concerns the ownership, use, validity or enforceability of any Intellectual Property Rights or Confidential
Information of the Company and its Subsidiaries and the Company’s and its Subsidiaries’ use of any Intellectual Property
Rights or Confidential Information owned by a third party, and, to the Company’s Knowledge, there is no valid basis for
the same.

 

    11 

     

    

 

3.15       Litigation.
With such exceptions that, individually or in the aggregate, are not reasonably expected to have a Material Adverse Effect, there
is no litigation or governmental proceeding pending or, to the Company’s Knowledge, threatened, against the Company or any
of its Subsidiaries or affecting any of the properties or assets of the Company or any of its Subsidiaries. Neither the Company
nor any Subsidiary is in default with respect to any order, writ, injunction, decree, ruling or decision of any court, commission,
board or other government agency that is expressly applicable to the Company or any Subsidiary or any of their assets or property.

 

3.16       Insurance
Coverage. The Company and each Subsidiary maintains insurance coverage that is customary for comparably situated companies
for the business being conducted and properties owned or leased by the Company and each Subsidiary. All such insurance is fully
in force, except where the failure to be in full force has not had and would not, individually or in the aggregate, be reasonably
expected to have a Material Adverse Effect.

 

3.17       Compliance
with Nasdaq Continued Listing Requirements. Except as described in the SEC Filings, the Company is in compliance with applicable
Nasdaq continued listing requirements. Except as described in the SEC Filings, there are no proceedings pending or, to the Company’s
Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has
not received any notice of, nor to the Company’s Knowledge is there any basis for, the delisting of the Common Stock from
Nasdaq. The issuance by the Company of the Stock Consideration shall not have the effect of delisting or suspending the Common
Stock from Nasdaq.

 

3.18       Brokers
and Finders. No Person will have, as a result of the transactions contemplated hereby or by the Private Placement Investment
Documents, any valid right, interest or claim against or upon the Company, any Subsidiary or an TCV Holder for any commission,
fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company,
other than as described in Schedule 3.18. The Company shall pay, and hold each TCV Holder harmless against, any liability,
loss or expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any
such claim.

 

3.19       Transactions
with Affiliates. Except as disclosed in the SEC Filings or as disclosed on Schedule 3.19, none of the officers or directors
of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction
with the Company or any Subsidiary (other than as holders of stock options and/or warrants, and for services as employees, officers
and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing
for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee
or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest
or is an officer, director, trustee or partner.

 

    12 

     

    

 

3.20       Internal
Controls. The Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002, as amended, and any
and all applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof and that are
currently applicable to the Company. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient
to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain
accountability for assets, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets and liabilities is compared with the existing
assets and liabilities at reasonable intervals and appropriate action is taken with respect to any differences. The Company has
established and maintains disclosure controls and procedures (as such term is defined in Rule 13a-15 and 15d-15 under the Exchange
Act). Such disclosure controls and procedures are designed to provide reasonable assurance that material information relating
to the Company, including its Subsidiaries, that is required to be disclosed by the Company in the reports that it furnishes or
files under the Exchange Act is reported within the time periods specified in the rules and forms of the SEC and that such material
information is communicated to the Company’s management to allow timely decisions regarding required disclosure. To the
Company’s Knowledge, there is no (i) significant deficiency in the design or operation of internal controls which could
adversely affect the Company’s or any of its Subsidiary’s ability to record, process, summarize and report financial
data or any material weaknesses in internal controls; or (ii) fraud, whether or not material, that involves management or other
employees who have a significant role in the Company’s or any of its Subsidiary’s internal controls.

 

3.21       Off
Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any of its
Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its Exchange
Act filings and is not so disclosed or that otherwise would be reasonably likely to have a Material Adverse Effect.

 

3.22       Investment
Company. Neither the Company nor any of its Subsidiaries is, and immediately after giving effect to the sale of the Shares
in accordance with this Agreement and the application of the proceeds thereof will not be required to be registered as, an “investment
company” or a company “controlled” by an “investment company,” within the meaning of the Investment
Company Act of 1940, as amended.

 

3.23       Sufficient
Funds. Assuming the concurrent consummation of the Concurrent Private Placement, the Company has sufficient cash or other
sources of immediately available funds to pay the Cash Consideration at the Closing in accordance with this Agreement.

 

3.24       Solvency.
At and immediately after the Closing, each of the Company and its Subsidiaries (a) will be solvent (in that both the fair value
of its assets will not be less than the sum of its debts and that the present fair saleable value of its assets will not be less
than the amount required to pay its probable liability on its recourse debts as they mature or become due), (b) will have adequate
capital and liquidity with which to engage in its business and (c) will not have incurred and does not plan to incur debts beyond
its ability to pay as they mature or become due.

 

    13 

     

    

 

3.25       Delaware
Section 203. The Board at a duly held meeting of the board prior to execution and delivery of this Agreement by the Company
approved the issuance of the Stock Consideration to the TCV Holders and the other transactions contemplated by this Agreement
for purposes of Section 203 of the General Corporation Law of the State of Delaware.

 

3.26       Conduct
of Business. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default under its Certificate
of Incorporation, any certificate of designations, preferences or rights of any other outstanding series of Preferred Stock of
the Company or any of its Subsidiaries or Bylaws or their organizational charter, certificate of formation or certificate of incorporation
or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any judgment, decree or order or any
statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and neither the Company nor any of
its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases for possible violations which
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

 

3.27       Compliance
with Anti-Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times
in compliance with applicable financial recordkeeping and reporting requirements and all other applicable U.S. and non-U.S. anti-money
laundering laws and regulations, including, but not limited to, those of the Currency
and Foreign Transactions Reporting Act of 1970, as amended, the USA Patriot Act of 2001 and the applicable money laundering statutes
of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”),
and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any of its Subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company,
threatened.

 

3.28       No
Conflicts with Sanctions Laws. Neither the Company nor any of its Subsidiaries, nor to the Company’s Knowledge, any
director, officer, employee, agent, Affiliate or other person associated with or acting on behalf of the Company or any of its
Subsidiaries or Affiliates is, or is directly or indirectly owned or controlled by, a Person that is currently the subject or
the target of any sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign
Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Departments of State or Commerce
and including, without limitation, the designation as a “specially designated national” or “blocked person”),
the United Nations Security Council (“UNSC”), the European Union, Her Majesty’s Treasury (“HMT”)
or any other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or any of its Subsidiaries
located, organized or resident in a country or territory that is the subject or target of a comprehensive embargo or Sanctions
prohibiting trade with the country or territory, including, without limitation, Cuba, Iran, North Korea, Sudan and Syria (each,
a “Sanctioned Country”); no action of the Company or any of its Subsidiaries in connection with the execution,
delivery and performance of this Agreement and the Private Placement Investment Documents or the consummation of any other transaction
contemplated hereby or thereby or the fulfillment of the terms hereof or thereof, will result in the proceeds of the transactions
contemplated hereby or thereby being used, or loaned, contributed or otherwise made available, directly or indirectly, to any
Subsidiary, joint venture partner or other person or entity, for the purpose of (i)
unlawfully funding or facilitating any activities of or business with any person that, at the time of such funding or facilitation,
is the subject or target of Sanctions, (ii) unlawfully funding or facilitating any activities of or business in any Sanctioned
Country or (iii) in any other manner that will result in a violation by any Person (including any Person participating in the
transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, or since the Company’s
or such subsidiary’s formation, whichever is more recent, the Company and its Subsidiaries have not knowingly engaged in
and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction
is or was the subject or the target of Sanctions or with any Sanctioned Country.

 

    14 

     

    

 

3.29       Anti-Bribery.
Neither the Company nor any of its Subsidiaries, nor to the Company’s Knowledge, any director, officer, employee, agent,
Affiliate or other person associated with or acting on behalf of the Company, or any of its Subsidiaries or
Affiliates, has (i) used any funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political
activity, (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee, to any
employee or agent of a private entity with which the Company does or seeks to do business (a “Private Sector Counterparty”)
or to foreign or domestic political parties or campaigns from corporate funds, (iii) violated or is in violation of any provision
of any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions or any applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”),
the U.K Bribery Act 2010, or any other similar law of any other jurisdiction in which the Company operates its business, including,
in each case, the rules and regulations thereunder, (iv) taken, is currently taking or will take any action in furtherance of
an offer, payment, gift or anything else of value, directly or indirectly, to any person while knowing that all or some portion
of the money or value will be offered, given or promised to anyone to improperly influence official action, to obtain or retain
business or otherwise to secure any improper advantage or (v) otherwise made any bribe, rebate, payoff, influence payment, unlawful
kickback or other unlawful payment; the Company and each of its respective Subsidiaries has instituted and has maintained, and
will continue to maintain, policies and procedures reasonably designed to promote and achieve compliance with the laws referred
to in (iii) above and with this representation and warranty; and none of the Company, nor any of its Subsidiaries or Affiliates
will directly or indirectly use the proceeds of the transactions contemplated hereby or by the Private Placement Investment
Documents or lend, contribute or otherwise make available such proceeds to any subsidiary,
Affiliate, joint venture partner or other person or entity for the purpose of financing or facilitating any activity that would
violate the laws and regulations referred to in (iii) above. 

 

3.30       Shell
Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

3.31       No
Disqualification Events. With respect to Stock Consideration to be issued and sold hereunder, none of the Company, any of
its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering
hereunder, any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the
basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company
in any capacity at the time of sale (each, an “Issuer Covered Person” and, together, “Issuer Covered
Persons”) is subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a “Disqualification Event”), except for a Disqualification Event covered by Rule
506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a
Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e),
and has furnished to the TCV Holders a copy of any disclosures provided thereunder.

 

    15 

     

    

 

3.32       Manipulation
of Price. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any
action designed to cause or to result, or that could reasonably be expected to cause or result, in the stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii) other than the Persons
set forth on Schedule 3.18, sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the
Shares, or (iii) other than the Persons set forth on Schedule 3.18, paid or agreed to pay to any Person any compensation
for soliciting another to purchase any other securities of the Company.

 

3.33       No
Other Representations. Except for the representations and warranties contained in Article II of this Agreement, the
Company acknowledges that neither TCV Holder nor any person on behalf of either TCV Holder makes, and the Company has not relied
upon, any other express or implied representation or warranty with respect to either TCV Holder or with respect to any other information
provided to the Company in connection with the transactions contemplated by this Agreement.

 

Article
IV

ADDITIONAL AGREEMENTS

 

4.1         Investor
Rights Agreement. The Parties hereby acknowledge and agree that the terms and provisions of the Investor Rights
Agreement shall continue in full force and effect, including all such terms and provisions that are applicable to the
Registrable Securities (as defined in the Investor Rights Agreement), which the parties agree shall apply to and include the
Stock Consideration in all respects and that the Stock Consideration shall be treated as Registrable Securities for all
purposes under the Investor Rights Agreement; provided, however, that (a) no Demand Notice (as defined in the
Investor Rights Agreement) will be made by the TCV Holders pursuant to Section 5 of the Investor Rights Agreement with
respect to the Stock Consideration prior to the 90th day following the issuance of the Stock Consideration, (b) on the 90th
day following the issuance of the Stock Consideration, the TCV Holders shall be deemed to have delivered, and the Company
shall be deemed to have received, a Demand Notice in accordance with Section 5(a) of the Investor Rights Agreement with
respect to a Demand Shelf Registration (as defined in the Investor Rights Agreement) covering the resale of all of the Stock
Consideration as Registrable Securities, and, upon further notice from the TCV Holders to the Company, the TCV Holders may
specify that the sale of all or a portion of the Stock Consideration constituting Registrable Securities is to be conducted
as an underwritten offering off of such Demand Shelf Registration pursuant to Section 5(f) and the other terms of the
Investor Rights Agreement, and (c) such deemed Demand Notice shall be treated as an additional Demand Notice under Section
5(a) of the Investor Rights Agreement made in accordance with and subject to the terms and conditions thereof (including
Section 8 of the Investor Rights Agreement), and shall be in addition to, and shall not reduce, the one Demand Notice that
the Holders owning a majority of the Registrable Securities are currently entitled to pursuant to Section 5(a) of the
Investor Rights Agreement, including a Demand Notice specifying that the sale of Registrable Securities is to be
conducted through an underwritten offering pursuant to Section 5(f) of the Investor Rights Agreement. Pursuant to Section 7
of the Investor Rights Agreement, the TCV Holders, holding a majority of the Registrable Securities, hereby consent to the
grant of registration rights to the investors in the Concurrent Private Placement as contemplated by the New Registration
Rights Agreement; provided that such registration rights are pari passu with or junior to the rights of the TCV
Holders as holders of Registrable Securities pursuant to the Investor Rights Agreement; and provided further that the
investors in the Concurrent Private Placement shall not have any “piggyback” or similar participation rights with
respect to any Demand Shelf Registration, including any underwritten offering of Registrable Securities made pursuant to a
Demand Shelf Registration.

 

    16 

     

    

 

4.2         Securities
Purchase Agreement; Short Sales.

 

(a)       The
Company and each of the TCV Holders agree that effective as of the consummation of the Closing, the Securities Purchase Agreement
and any confidentiality or non-disclosure agreement between or among the Company and the TCV Holders shall terminate in its entirety,
and the Company and the TCV Holders shall have no further rights or obligations thereunder.

 

(b)       Each
TCV Holder agrees that for so long as such TCV Holder or any of its Restricted Affiliates (as defined below) owns any of the shares
of Common Stock constituting the Stock Consideration, it will not, and it will not cause, suffer or permit any of its Restricted
Affiliates to, enter into any Short Sales (as defined below). Notwithstanding the foregoing, the Company and the TCV Holders agree
that nothing in this Section 4.2(b) shall restrict the ability of a TCV Holder or any of its Restricted Affiliates to outright
sell, distribute or transfer any of the shares of Common Stock constituting the Stock Consideration.

 

(c)       For
purposes of Section 4.2, “Restricted Affiliate” means: (i) any individual, corporation, partnership,
limited liability company, joint venture, trust or unincorporated organization or a government or agency or political subdivision
thereof (each, a “Person”) who is directly or indirectly responsible for the formation, management, operations,
oversight or administration of the TCV Holders (including, without limitation, any principals, partners or employees of any such
Person); (ii) any investment fund directly or indirectly formed or controlled by any one or more Persons referred to in the preceding
clause (i); and (iii) any direct or indirect subsidiary (as defined in Rule 1-02(x) of Regulation S-X promulgated by the SEC,
a “Subsidiary”) of any Person referred to in the preceding clauses (i) or (ii) in which any one or more such
Persons have the right to elect (directly or indirectly) a majority of the board of directors (or a comparable governing body
with a different name) of such Subsidiary or own a majority of the voting securities entitled to elect the board of directors
(or comparable governing body with a different name) of such Subsidiary. For purposes of Section 4.2, “Short Sale”
means: (i) a sale of Common Stock that is marked as a short sale; (ii) any entering into or establishment of any arrangement constituting
a “put equivalent position,” as defined by Rule 16a-1(h) promulgated under the Securities Exchange Act of 1934, as
amended; (iii) entering into any swap, option or any other agreement or any transaction that transfers, in whole or in part, directly
or indirectly, the economic consequence of ownership of Common Stock, whether any such swap or transaction is to be settled by
delivery of Common Stock or other securities, in cash or otherwise; or (iv) the announcement of any intent to do any of the foregoing.

 

    17 

     

    

 

4.3         Tax
Treatment. The exchange of the Series B Preferred Stock for the Stock Consideration and the Cash Consideration pursuant to
this Agreement is intended to qualify as a recapitalization within the meaning of Section 368(a)(1)(E) of the Internal Revenue
Code of 1986, as amended (the “Code”), with the Stock Consideration and the Cash Consideration having been
received pursuant to Section 354(a)(1) of the Code and Section 356(a)(1)(B) of the Code, respectively, and this Agreement shall
constitute a “plan of reorganization” described in Treasury Regulations Section 1.368-1(c). The parties agree to prepare
and file their U.S. federal, state and local income tax returns in a manner consistent with the foregoing sentences of this Section
4.4 and shall not take any tax position inconsistent therewith for tax purposes, including income tax purposes.

 

4.4         Form
D, Blue Sky and Nasdaq. The Company agrees to file a Form D with respect to the Stock Consideration as required under Regulation
D and to provide a copy thereof to each TCV Holder promptly after such filing. The Company shall take such action as the Company
shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Stock Consideration for sale to
the TCV Holders at the Closing pursuant to this Agreement under applicable securities or “blue sky” laws of the states
of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken
to the TCV Holders. The Company shall make all filings and reports relating to the offer and sale of the Stock Consideration required
under applicable securities or “blue sky” laws of the states of the United States. The Company shall file with Nasdaq
a Notification Form: Listing of Additional Shares for the listing of the Stock Consideration on the Nasdaq Capital Market, a copy
of which shall be provided to the TCV Holders. 

 

4.5         Further
Assurance. From and after the date hereof, the TCV Holders and the Company shall execute and deliver such further instruments
of conveyance, transfer and assignment and shall take such other actions as a Party may reasonably request of another Party in
order to effectuate the purposes of this Agreement and carry out the terms hereof.

 

Article
V

Definitions

 

In
addition to terms defined elsewhere in this Agreement, the following terms when used in this Agreement will have the respective
meanings set forth below:

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls,
is controlled by, or is under common Control with, such Person.

 

“Company’s
Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the Securities Act) of
the Company, after due inquiry.

 

    18 

     

    

 

“Confidential
Information” means trade secrets, confidential information and know-how (including but not limited to ideas, formulae,
compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications,
support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related
information).

 

“Control”
(including the terms “controlling”, “controlled by” or “under common control with”) means
the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise.

 

“Intellectual
Property Rights” means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether
or not patentable and whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names, corporate
names, logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights
and copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer
software (including but not limited to data, data bases and documentation).

 

“Material
Adverse Effect” means a material adverse effect on (i) the assets, properties, liabilities, operations, results of operations,
condition (financial or otherwise), business, or prospects of the Company and its Significant Subsidiaries, individually or taken
as a whole, (ii) the transactions contemplated hereby or the Private Placement Investment Documents or (iii) the ability or authority
of the Company to perform its obligations under this Agreement or the Private Placement Investment Documents.

 

“Material
Contract” means any contract, instrument or other agreement to which the Company or any Subsidiary is a party or by
which it is bound which is material to the business of the Company and its Significant Subsidiaries, individually or taken as
a whole, including those that have been filed or were required to have been filed as an exhibit to the SEC Filings pursuant to
Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.

 

“Nasdaq”
means The Nasdaq Capital Market. 

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“SEC
Filings” has the meaning set forth in Section 3.7.

 

“Significant
Subsidiary” means each of Bankers Financial Products Corporation (d/b/a RateWatch), The Deal, LLC and Management Diagnostics
Limited (d/b/a BoardEx).

 

“Subsidiary”
of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests
of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such
voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person.

 

    19 

     

    

 

Article
VI

MISCELLANEOUS

 

6.1         Severability.
If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, illegal or unenforceable, such
provision shall be severed and enforced to the extent possible or modified in such a way as to make it enforceable, and the invalidity,
illegality or unenforceability thereof shall not affect the validity, legality or enforceability of the remaining provisions of
this Agreement.

 

6.2         Governing
Law. This Agreement shall be construed and enforced in accordance with and governed by the Laws of the State of New York without
regard to the conflicts of laws principles thereto.

 

6.3         Consent
to Jurisdiction; Waiver of Jury Trial. Each Party hereby submits to the exclusive jurisdiction of the courts of the State
of New York located in New York County and the United States District Court for the Southern District of New York any action arising
out of or relating to this Agreement and agrees that all claims in respect of such action may be heard and determined in any such
court. Each Party waives any defense of inconvenient forum to the maintenance of any action so brought. Any Party may make service
on the other Party by sending or delivering a copy of the process to the Party to be served at the address and in the manner provided
for the giving of Notices in Section 6.5. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY THAT MAY ARISE UNDER
THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY
WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTIONS, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE
OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER
IN THE EVENT OF AN ACTION, (B) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY,
AND (D) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS SECTION 6.3.

 

6.4         Remedies.
The Company and the TCV Holders agree that irreparable damage would occur and that the other Parties would not have any adequate
remedy at law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms
or were otherwise breached. Accordingly, the Company and the TCV Holders shall without the necessity of proving the inadequacy
of money damages or posting a bond be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and
to enforce specifically the terms, provisions and covenants contained herein, this being in addition to any other remedy to which
they are entitled at law or in equity. No failure or delay of any Party in exercising any right or remedy hereunder shall operate
as a waiver thereof, nor will any single or partial exercise of any right or power, or any abandonment or discontinuance of steps
to enforce such right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The
rights and remedies of the Parties hereunder are cumulative and are not exclusive of any rights or remedies that they would otherwise
have hereunder.

 

    20 

     

    

 

6.5         Notices.
All notices, demands, consents, approvals, requests or other communications which any of the Parties may desire or be required
to give hereunder (collectively, “Notices”) shall be in writing and shall be given by a nationally recognized
overnight courier, facsimile (or like transmission) or by PDF via email and addressed as follows:

 

If
to a TCV Holder:

 

Technology
Crossover Ventures 

528
Ramona Street 

Palo
Alto, California 94301 

Attention:
General Counsel 

Facsimile:
(650) 618-1989 

Email:
legal@tcv.com

 

With
a copy to (which shall not constitute notice to such TCV Holder):

 

Latham
& Watkins LLP

140 Scott Drive 

Menlo
Park, California 94025 

Attention:
Joshua M. Dubofsky 

Facsimile:
(650) 463-2600 

Email:
josh.dubofsky@lw.com

 

If
to the Company:

 

TheStreet,
Inc. 

14
Wall Street, 15th Floor 

New
York, New York 10005 

Attention:
Heather Mars, General Counsel 

Facsimile:
(212) 321-5015 

Email:
heather.mars@thestreet.com

 

With
a copy to (which shall not constitute notice to the Company):

 

Orrick,
Herrington & Sutcliffe LLP 

405
Howard Street 

San
Francisco, California 94105

Attention: Karen Dempsey

Fax: (415) 773-5759 

Email:
kdempsey@orrick.com

 

    21 

     

    

 

The
Company or the TCV Holders may change its address for Notices hereunder by a Notice given pursuant to this Section 6.5.
A Notice sent in compliance with the provisions of this Section 6.5 shall be deemed given on the first business day following
the day on which the Notice was delivered to an overnight courier or, if notice is given by facsimile or email, upon confirmation
of transmission by the transmitting equipment or email confirmation that such notice was received, as the case may be.

 

6.6         Expenses.
All fees, costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including accounting
and legal fees shall be paid by the party incurring such expenses, except that, upon consummation of the transactions contemplated
hereby, the Company shall pay up to $50,000 of the reasonable and documented out-of-pocket fees and expenses incurred by the TCV
Holders, including the reasonable and documented fees and expenses of counsel for the TCV Holders. 

 

6.7         Indemnification.
In consideration of each TCV Holder’s execution and delivery of this Agreement and in addition to all of the Company’s
other obligations hereunder, the Company shall defend, protect, indemnify and hold harmless each TCV Holder and all of their stockholders,
partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’ agents
or other representatives (including, without limitation, those retained in connection with the transactions contemplated by this
Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action, suits,
claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether
any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’
fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising
out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in this Agreement
or any other certificate, instrument or document contemplated hereby, (b) any breach of any covenant, agreement or obligation
of the Company contained in this Agreement or any other certificate, instrument or document contemplated hereby or (c) any cause
of action, suit or claim brought or made against such Indemnitee by a third party (including for these purposes a derivative action
brought on behalf of the Company) and arising out of or resulting from (i) the execution, delivery, performance or enforcement
of this Agreement or any other certificate, instrument or document contemplated hereby, other than claims for indemnification
within the scope of Section 10 of the Investor Rights Agreement, (ii) any transaction used to finance in whole or in part, directly
or indirectly, the Cash Consideration, the exchange of the Series B Preferred Stock or the other transactions contemplated hereby,
including the Concurrent Private Placement, or (iii) the status of such TCV Holder as an investor in the Company pursuant to the
transactions contemplated by this Agreement, except, in each case, with respect to any Indemnified Liabilities that resulted solely
from any TCV Holder’s gross negligence, willful misconduct or fraud. To the extent that the foregoing undertaking by the
Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of
each of the Indemnified Liabilities that is permissible under applicable law. Except as otherwise set forth herein, the mechanics
and procedures with respect to the rights and obligations under this Section 6.7 shall be the same as those set forth in
Section 10 of the Investor Rights Agreement.

 

    22 

     

    

 

6.8         References,
Pronouns and Headings. Except as otherwise specifically indicated, all references to Section or Subsection numbers refer to
Sections and Subsections of this Agreement and all references to Exhibits refer to the Exhibits attached hereto. The words “hereby,”
“hereof,” “herein,” “hereto,” “hereunder,” and words of similar import refer to
this Agreement as a whole and not to any particular Section or Subsection hereof. The word “hereafter” shall mean
after, and the term “heretofore” shall mean before, the date of this Agreement. The word “including” shall
not be construed as terms of limitation. As used herein, all pronouns shall include the masculine, feminine, neuter, singular
and plural thereof wherever the context and facts require such construction. The headings, titles and subtitles herein are inserted
for convenience of reference only and are to be ignored in any construction of the provisions hereof.

 

6.9         Successors
and Assigns. Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or
on behalf of any of the Parties will bind and inure to the benefit of the respective permitted successors and assigns of the Parties,
whether so expressed or not.

 

6.10       Entire
Agreement. This Agreement (together with the Investor Rights Agreement) among the Company and the TCV Holders constitutes
the entire agreement among the Parties with respect to the subject matter hereof and supersedes all prior agreements, understandings
and negotiations, both written and oral, between the Parties with respect to the subject matter hereof or thereof. No representation,
inducement, promise, understanding, condition or warranty not set forth in this Agreement (or in any other agreements contemplated
hereby) has been made or relied upon by any Party. This Agreement is not intended to confer upon any person other than the Parties
any rights or remedies hereunder. This Agreement may not be modified or amended and no provision hereof may be waived except by
an instrument or instruments in writing signed by each Party hereto.

 

6.11       Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together shall constitute
one and the same instrument, and all signatures need not appear on any one counterpart. The exchange of a fully executed Agreement
(in counterparts or otherwise) by facsimile or by electronic delivery in PDF format shall be sufficient to bind the Parties to
the terms and conditions of this Agreement.

 

[Signature
page follows]

 

    23 

     

    

 

The
Parties have executed this Exchange Agreement as of the date first above written.

 

	 	THESTREET, INC.	 
	 	 	 	 
	 	By:	/s/
    David A. Callaway	 
	 	Name: David A. Callaway	 
	 	Title:   Chief Executive Officer	 
	 	 	 	 
	 	TCV VI, L.P.	 
	 	By:	Technology
Crossover Management VI, L.L.C.	 
	 	Its:	General
    Partner	 
	 	 	 	 
	 	By:	/s/ Frederick D. Fenton
	 	Name: Frederick D. Fenton	 
	 	Title:   Attorney in Fact	 
	 	 	 	 
	 	TCV MEMBER FUND, L.P.	 
	 	By:	Technology
Crossover Management VI, L.L.C.	 
	 	Its:	General
    Partner	 
	 	 	 	 
	 	By:	/s/ Frederick D. Fenton
	 	Name: Frederick D. Fenton	 
	 	Title:   Attorney in Fact	 

 

     

     

    

 

Exhibit
A

 

	Holder	 	Number of Shares of
 Series B Preferred Stock	 	 	Number of Shares of
 Stock Consideration	 	 	Amount of Cash Consideration	 
	TCV VI, L.P.	 	 	5,455.95095	 	 	 	5,951,946	 	 	$	19,839,821.64	 
	TCV Member Fund, L.P.	 	 	44.04905	 	 	 	48,054	 	 	$	160,178.36	 
	Total	 	 	5,500.00	 	 	 	6,000,000	 	 	$	20,000,000.00	 

 

     

     

    

 

Disclosure
Schedules

 

These
are the “Disclosure Schedules” referred to in the Exchange Agreement dated as of November 10, 2017 (the “Exchange
Agreement”) among TheStreet, Inc., a Delaware corporation, TCV VI, L.P., a Delaware limited partnership, and TCV Member
Fund, L.P., a Cayman Islands exempted limited partnership. Capitalized terms used but not defined herein have the meanings assigned
to them in the Exchange Agreement.

 

Schedule
3.1        Organization and Power.

 

Subsidiaries
of the Company:

 

	Entity 
	 	Jurisdiction
of Organization 

	Bankers
    Financial Products Corporation	 	Wisconsin
	BankingMyWay.com,
    LLC	 	Wisconsin
	Boardex
    LLC	 	Delaware
	Management
    Diagnostics Limited	 	United
    Kingdom
	MDL
    ESOP Limited	 	United
    Kingdom
	SP-TSC
    Holdings LLC	 	Delaware
	Stockpickr
    LLC	 	Delaware
	The
    Deal L.L.C.	 	Delaware

 

Schedule
3.5(c)(ii)             Capitalization.

 

The
transactions contemplated by the following:

 

a.           Employment
Agreement dated as of November 8, 2017, between James J. Cramer and the Company (the “Cramer Employment Agreement”).

 

Schedule
3.8        No Material Adverse Change.

 

The
transactions contemplated by the following:

 

b.           Cramer
Employment Agreement.

 

     DS-1

     

    

 

Schedule
3.13      Labor Matters.

 

The
following agreements:

 

a.           Cramer
Employment Agreement.

 

Schedule
3.18      Brokers and Finders.

 

The
following agreements: 

 

a.           Letter
Agreement, dated September 11, 2017, between TheStreet, Inc. and Lake Street Capital Markets, LLC.

 

b.           Letter
Agreement, dated November 7, 2017, between TheStreet, Inc. and B. Riley FBR, Inc.

 

Schedule
3.19      Transactions with Affiliates.

 

The
transactions contemplated by the following:

 

a.           Cramer
Employment Agreement.

 

    DS-2Exhibit 10.2

 

Execution Version

 

 

SECURITIES
PURCHASE AGREEMENT

 

THIS SECURITIES PURCHASE
AGREEMENT (this “Agreement”) dated as of November 10, 2017, by and among TheStreet, Inc., a Delaware corporation
(the “Company”), and each of those entities (each an “Investor” and collectively the “Investors”)
listed on the Schedule of Investors attached as Exhibit A (the “Schedule of Investors”).

 

Recitals

 

WHEREAS, the Company
and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by Section 4(a)(2) of the 1933 Act (as defined herein) and Rule 506 of Regulation D as promulgated by the U.S. Securities
and Exchange Commission (the “SEC”) thereunder;

 

WHEREAS, the Investors
wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms and conditions stated
in this Agreement, an aggregate of $7,849,999.30 (the “Purchase Price”) of the Company’s shares (the “Shares”)
of common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $1.10 per Share (the
“Per Share Price”);

 

WHEREAS, contemporaneous
with the sale of the Shares, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached
hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company will agree to
provide certain registration rights under the 1933 Act and the rules and regulations promulgated thereunder, and applicable state
securities laws;

 

WHEREAS, concurrently
with the consummation of the transactions contemplated hereby, the Company proposes to enter into an exchange agreement (the “TCV
Agreement”) with entities affiliated with Technology Crossover Ventures (collectively, “TCV”), pursuant
to which TCV will exchange all of the shares of the Company’s Series B convertible preferred stock held by TCV in exchange
for an aggregate of (i) 6,000,000 newly issued shares of Common Stock (the “TCV Shares”) and (ii) an amount
in cash equal to $20,000,000 (such exchange and related transactions, the “TCV Exchange”);

 

WHEREAS, the consummation
of the transactions contemplated hereby shall occur concurrently with, and be conditioned on, the consummation of such TCV Exchange.

 

NOW, THEREFORE, in
consideration of the premises and the mutual representations, warranties, covenants and agreements contained herein, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.            Definitions. In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement,
the following terms shall have the meanings set forth below:

 

“1933 Act”
means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

     

     

    

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is
controlled by, or is under common Control with, such Person.

 

“Agent”
means Lake Street Capital Markets, LLC.

 

“Business Day”
means any day, other than a Saturday or Sunday or other day, on which banks in the City of New York are authorized or required
by law or executive order to remain closed.

 

“Company’s
Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company,
after due inquiry.

 

“Confidential
Information” means trade secrets, confidential information and know-how (including but not limited to ideas, formulae,
compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications,
support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related
information).

 

“Control”
(including the terms “controlling”, “controlled by” or “under common control with”) means the
possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether
through the ownership of voting securities, by contract or otherwise.

 

“Effective Date”
means the date on which the initial Registration Statement is declared effective by the SEC.

 

“Effectiveness
Deadline” means the date on which the initial Registration Statement is required to be declared effective by the SEC
under the terms of the Registration Rights Agreement.

 

“Insolvent”
means, with respect to any Person, (i) the present fair saleable value of such Person’s assets is less than the amount required
to pay such Person’s total indebtedness, (ii) such Person is unable to pay its debts and liabilities, subordinated, contingent
or otherwise, as such debts and liabilities become absolute and matured, (iii) such Person intends to incur or believes that it
will incur debts that would be beyond its ability to pay as such debts mature or (iv) such Person has unreasonably small capital
with which to conduct the business in which it is engaged as such business is now conducted and is proposed to be conducted.

 

“Intellectual
Property Rights” means all of the following: (i) patents, patent applications, patent disclosures and inventions
(whether or not patentable and whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names,
corporate names, logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights
and copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary
computer software (including but not limited to data, data bases and documentation).

 

    2

     

    

 

“Material Adverse
Effect” means a material adverse effect on (i) the assets, properties, liabilities, operations, results of operations,
condition (financial or otherwise), business, or prospects of the Company and its Significant Subsidiaries, individually or taken
as a whole, (ii) the transactions contemplated hereby or the other Transaction Documents or (iii) the ability or authority
of the Company to perform its obligations under the Transaction Documents.

 

“Material Contract”
means any contract, instrument or other agreement to which the Company or any Subsidiary is a party or by which it is bound which
is material to the business of the Company and its Significant Subsidiaries, individually or taken as a whole, including those
that have been filed or were required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10)
of Regulation S-K.

 

“Nasdaq”
means The Nasdaq Capital Market.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Registration
Statement” has the meaning set forth in the Registration Rights Agreement.

 

“SEC Filings”
has the meaning set forth in Section 4.6.

 

“Significant
Subsidiary” means each of Bankers Financial Products Corporation (d/b/a RateWatch), The Deal, LLC and Management Diagnostics
Limited (d/b/a BoardEx).

 

“Subsidiary”
of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests
of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such
voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person.

 

“Transaction
Documents” means this Agreement and the Registration Rights Agreement.

 

2.            Purchase and Sale of the Shares. Subject to the terms and conditions of this Agreement, on the Closing Date, each
Investor shall severally, and not jointly, purchase, and the Company shall sell and issue to each Investor, the Shares in the amounts
set forth opposite each such Investor’s name on the Schedule of Investors in exchange for the portion of the Purchase Price
equal to the Per Share Price multiplied by the number of Shares to be purchased by such Investor as specified in Section 3
below.

 

    3

     

    

 

3.            Closing. Upon confirmation that the other conditions to closing specified herein have been satisfied or duly waived
by the Investors, the Company shall cause to be issued and delivered to each Investor book-entry notations registered in such Investor’s
name, representing the Shares that such Investor is purchasing against payment of such Investor’s pro rata portion of the
Purchase Price therefor as set forth opposite such Investor’s name on the Schedule of Investors by a wire transfer in same
day funds to be sent to the account of the Company as instructed in writing by the Company. On the date (the “Closing
Date”) the Company receives the Purchase Price, the book-entry notations evidencing the Shares shall be delivered to
the Investors (the “Closing”). The Closing of the purchase and sale of the Shares shall take place at the offices
of Orrick, Herrington & Sutcliffe LLP at 405 Howard Street, San Francisco, California concurrently or promptly following the
satisfaction or waiver of the conditions to the obligations of the parties hereto set forth in Section 6 occurs or at such
other location and on such other date as the Company and the Investors shall mutually agree.

 

4.            Representations and Warranties of the Company. The Company hereby represents and warrants to the Investors that,
except as set forth in the SEC Filings where specifically referenced or on the corresponding sections of the schedules delivered
herewith (collectively, the “Disclosure Schedules”):

 

4.1           Organization, Good Standing and Qualification. Each of the Company and its Subsidiaries is duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization (to the
extent the concept of good standing is recognized in the relevant jurisdiction) and has all requisite power and authority to carry
on its business as now conducted and to own or lease its properties. Each of the Company and its Subsidiaries is duly qualified
to do business as a foreign corporation or other entity and is in good standing in each jurisdiction (to the extent the concept
of good standing is recognized in the relevant jurisdiction) in which the conduct of its business or its ownership or leasing of
property makes such qualification or leasing necessary unless the failure to be in good standing or so qualify has not had and
could not reasonably be expected to have a Material Adverse Effect. The Company’s Subsidiaries are listed on Schedule 4.1
hereto.

 

4.2           Authorization. The Company has all corporate power and authority and has taken all requisite action on the part of
the Company, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of the Transaction
Documents, (ii) the authorization of the performance of all obligations of the Company hereunder or thereunder, and (iii) the
authorization, issuance and delivery of the Shares, and no further filing, consent or authorization is required by the Company,
its Board of Directors or its stockholders. This Agreement and the other Transaction Documents have been duly executed and delivered
by the Company, and assuming due execution and delivery thereof by each of the other parties thereto, the Transaction Documents
constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms,
except as such enforceability may be limited by applicable laws relating to bankruptcy, insolvency, reorganization, moratorium
or other similar legal requirement relating to or affecting creditors’ rights generally and except as such enforceability
is subject to general principles of equity (regardless of whether enforceability is considered in a proceeding in equity or at
law).

 

    4

     

    

 

4.3           Capitalization. Schedule 4.3(1) sets forth as of the date hereof, (a) the authorized capital stock
of the Company; (b) the number of shares of capital stock issued and outstanding; (c) the number of shares of capital
stock issuable pursuant to the Company’s stock plans; and (d) the number of shares of capital stock issuable and reserved
for issuance pursuant to securities exercisable for, or convertible into or exchangeable for any shares of capital stock of the
Company. All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued
and are fully paid, nonassessable and free of pre-emptive rights and were issued in full compliance with applicable state and federal
securities law and were not issued in violation of any pre-emptive right, resale right, right of first refusal or similar right.
All of the issued and outstanding shares of capital stock of each Subsidiary have been duly authorized and validly issued and are
fully paid, nonassessable and free of pre-emptive rights, were issued in full compliance with applicable state and federal securities
law and were not issued in violation of any pre-emptive right, resale right, right of first refusal or similar right and are owned
by the Company, beneficially and of record, subject to no lien, encumbrance or other adverse claim. No Person is entitled to pre-emptive
or similar statutory or contractual rights with respect to any securities of the Company. Except as described on Schedule 4.3(2),
there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any character
under which the Company or any of its Subsidiaries is or may be obligated to issue any equity securities of any kind and except
as contemplated by this Agreement, neither the Company nor any of its Subsidiaries is currently in negotiations for the issuance
of any equity securities of any kind. Except as described on Schedule 4.3(3) and except for the Registration Rights
Agreement, there are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements
of any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by them.
Except as described on Schedule 4.3(4) and except as provided in the Registration Rights Agreement, no Person has the
right to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection
with the registration of securities of the Company for its own account or for the account of any other Person. The issuance and
sale of the Shares hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person
(other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding
security. The Company does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement
in effect giving any Person the right to purchase any equity interest in the Company upon the occurrence of certain events.

 

4.4           Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement,
will be validly issued, fully paid and nonassessable, and shall be free and clear of all preemptive or similar rights (except for
those which have been validly waived prior to the date hereof), taxes, liens and charges and other encumbrances and restrictions
(other than those created by the Investors), except for restrictions on transfer set forth in this Agreement or imposed by applicable
securities laws.

 

4.5           Consents. The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance
and sale of the Shares require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency,
or official other than filings that have been made pursuant to applicable state securities laws and Nasdaq listing requirements,
post-sale filings pursuant to applicable state and federal securities laws which the Company undertakes to file within the applicable
time periods and those where the failure to obtain such consent, take such action or make such filing would not reasonably be expected
to result in a Material Adverse Effect.

 

    5

     

    

 

4.6          Delivery of SEC Filings; Business. The Company has made available to the Investors through the SEC’s EDGAR
system, true and complete copies of the Company’s reports, schedules, forms, statements and other documents required to be
filed by it with the SEC pursuant to the reporting requirements of the 1934 Act during the two (2) years prior to the date hereof
(collectively with all amendments, exhibits, financial statements, notes and schedules thereto, the “SEC Filings”).
The SEC Filings are the only filings required of the Company pursuant to the 1934 Act for such period. The Company and its Subsidiaries
are engaged in all material respects only in the business described in the SEC Filings.

 

4.7          Use of Proceeds. The net proceeds of the sale of the Shares shall be used by the Company for funding in part the
cash consideration to be paid in the TCV Exchange.

 

4.8          No Material Adverse Change. Since December 31, 2016, except as identified and described on Schedule 4.8,
there has not been:

 

(i)          any change in the consolidated assets, liabilities, financial condition or operating results of the Company from that reflected
in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017,
except for changes in the ordinary course of business which have not had and would not reasonably be expected to have a Material
Adverse Effect, individually or in the aggregate;

 

(ii)         any declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock
of the Company, or any redemption or repurchase of any securities of the Company;

 

(iii)        any material damage, destruction or loss, whether or not covered by insurance to any assets or properties of the Company
or its Subsidiaries;

 

(iv)        any waiver, not in the ordinary course of business, by the Company or any Subsidiary of a material right or of a material
debt owed to it;

 

(v)         any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company or a Subsidiary,
except in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results
or business of the Company and its Subsidiaries taken as a whole (as such business is presently conducted and as it is proposed
to be conducted);

 

(vi)        any change or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to any Material
Contract or arrangement by which the Company or any Subsidiary is bound or to which any of their respective assets or properties
is subject;

 

(vii)       any material labor difficulties or labor union organizing activities with respect to employees of the Company or any Subsidiary;

 

(viii)      any material transaction entered into by the Company or a Subsidiary other than in the ordinary course of business;

 

    6

     

    

 

(ix)         the loss of the services of any key employee, or material change in the composition or duties of the senior management of
the Company or any Subsidiary;

 

(x)          the loss, to the Company’s Knowledge, threatened loss of any customer which has had or could reasonably be expected
to have a Material Adverse Effect; or

 

(xi)         any other event or condition of any character that has had or could reasonably be expected to have a Material Adverse Effect.

 

4.9         
SEC Filings; Financial Information; S-3 Eligibility.

 

(a)          At the time of filing thereof, the SEC Filings complied as to form in all material respects with the requirements of the
1934 Act and, as of their respective dates, did not contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. To the Company’s Knowledge, the written information furnished by or on behalf
of the Company to any of the Investors prior to the date hereof in connection with the transactions contemplated hereby which is
not included in the SEC Filings (including, without limitation, information referred to in Section 5.6 of this Agreement
or in the disclosure schedules to this Agreement), taken as a whole, does not contain, as of the date furnished, any untrue statement
of a material fact or omits to state any material fact necessary in order to make the statements therein not misleading, in the
light of the circumstance under which they are or were made; provided that with respect to projections, forecasts, estimates,
budgets and other forward-looking statements and information that were prepared by the Company, the Company only represents that
such projections, forecasts, estimates, budgets and other forward-looking information were prepared in good faith upon assumptions
believed by the Company to be reasonable at the time made.

 

(b)          The financial statements included in each SEC Filing comply in all material respects with applicable accounting requirements
and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by
a subsequent restatement) and present fairly, in all material respects, the consolidated financial position of the Company as of
the dates shown and its consolidated results of operations and cash flows for the periods shown, and such financial statements
have been prepared in conformity with United States generally accepted accounting principles applied on a consistent basis (“GAAP”)
(except as may be disclosed therein or in the notes thereto, and, in the case of quarterly financial statements, except for normal
year-end audit adjustments and as otherwise as permitted by Form 10-Q under the 1934 Act).

 

(c)          The Company satisfies the “registrant requirements” for use of Form S-3 set forth in General Instruction I.A
to Form S-3 promulgated by the SEC.

 

    7

     

    

 

4.10        
No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by
the Company and the issuance and sale of the Shares will not (i) conflict with or result in a breach or violation of (a) any
of the terms and provisions of, or constitute a default under the Company’s Certificate of Incorporation or the Company’s
Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through
the SEC’s EDGAR system), or (b) any statute, rule, regulation or order of Nasdaq, any governmental agency or body or
any court, domestic or foreign, having jurisdiction over the Company, any Subsidiary or any of their respective assets or properties,
except as which have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate,
or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company
or any Subsidiary or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice,
lapse of time or both) of, any contract required to be filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item
601(b)(10) of Regulation S-K, except as which have not had and would not reasonably be expected to have a Material Adverse Effect,
individually or in the aggregate.

 

4.11        
Tax Matters. The Company and each of its Subsidiaries has filed all tax returns required to be filed by the Company
or such Subsidiary with all appropriate governmental agencies within the applicable periods for such filings (with due regard to
any extension) and has paid all taxes required to be paid, except for any such failures to file or pay that would not individually
or in the aggregate have a Material Adverse Effect. No material deficiencies for any tax are currently assessed against the Company
or any of its Subsidiaries, and no tax returns of the Company or any of its Subsidiaries have been audited during the last three
years, and, there is no such audit pending or, to the knowledge of the Company, contemplated. There is no outstanding claim by
an authority in a jurisdiction where the Company does not file tax returns that it is or may be subject to the imposition of any
material tax by that jurisdiction.

 

4.12        
Title to Properties. The Company and its Subsidiaries do not own any real property; except as disclosed in the SEC
Filings, the Company and each Subsidiary has good and marketable title to all personal property owned by it, in each case free
from liens, encumbrances and defects that would materially affect the value thereof or materially interfere with the use made or
currently planned to be made thereof by them; and except as disclosed in the SEC Filings, the Company and each Subsidiary holds
any leased real or personal property under valid and enforceable leases with no exceptions that would materially interfere with
the use made or currently planned to be made thereof by them.

 

4.13        
Certificates, Authorities and Permits. The Company and each Subsidiary possess adequate certificates, authorities
or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, except where
such failure has not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate,
and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of
any such certificate, authority or permit that, if determined adversely to the Company or such Subsidiary, would reasonably be
expected to have a Material Adverse Effect, individually or in the aggregate.

 

    8

     

    

 

4.14        
Labor Matters. Except as described on Schedule 4.14, the Company has described in, or filed as an exhibit
to, the SEC Filings filed prior to the date of this Agreement all of the following types of documents, agreements, plans or arrangements
that are required by federal securities laws to be described in, or filed as an exhibit to, the SEC Filings: employment agreements,
consulting agreements, deferred compensation, pension or retirement agreements or arrangements (including all “employee pension
benefit plans” as defined in Section 3(2) of ERISA, bonus, incentive or profit-sharing plans or arrangements, or labor
or collective bargaining agreements in effect by the Company and its Subsidiaries) (the “ERISA Documents”).
Except for any compliance failures that, individually or in the aggregate, would not reasonably be expected to have a Material
Adverse Effect, (a) the Company and its Subsidiaries are in compliance in all respects with all applicable laws and regulations
relating to labor, employment, fair employment practices, terms and conditions of employment, and wages and hours, and with the
terms of the ERISA Documents; and (b) each such ERISA Document is in compliance in all respects with all applicable requirements
of ERISA. To the Company’s Knowledge, none of the Company’s or its Subsidiaries’ employees are obligated under
any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree
or order of any court or administrative agency, that would interfere with the use of his or her employment obligations to the Company
or its Subsidiaries or that would conflict with the Company’s and its Subsidiaries’ business as now conducted or proposed
to be conducted, except for such contracts and other agreements, judgments, decrees and orders that would not, individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

4.15        
Intellectual Property. All Intellectual Property Rights purported to be owned by the Company or any of its Subsidiaries
that were developed, worked on or otherwise held by any employee, officer, consultant or otherwise are owned free and clear by
the Company or one of its Subsidiaries (as the case may be) by operation of law or have been validly assigned to the Company one
of its Subsidiaries (as the case may be) other than those Intellectual Property Rights where the failure to own or assign such
rights would not, individually or in its aggregate be reasonably likely to have a Material Adverse Effect. The Intellectual Property
Rights are sufficient in all material respects to carry on the business of the Company and each of its Subsidiaries as presently
conducted and as proposed to be conducted. To the knowledge of the Company, with such exceptions as are not, individually or in
the aggregate reasonably likely to have a Material Adverse Effect, the Intellectual Property Rights purported to be owned by the
Company or any of its Subsidiaries do not infringe the intellectual property rights of any third party. To the Knowledge of the
Company, the conduct of the Company’s and its Subsidiaries’ businesses as currently conducted does not infringe or
otherwise impair or conflict with (collectively, “Infringe”) any Intellectual Property Rights of any third party
or any confidentiality obligation owed to a third party, and, to the Company’s Knowledge, the Intellectual Property Rights
and Confidential Information of the Company and its Subsidiaries which are necessary for the conduct of Company’s and each
of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted are not being
Infringed by any third party. There is no litigation or order pending or outstanding or, to the Company’s Knowledge, threatened,
that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability of any Intellectual Property Rights
or Confidential Information of the Company and its Subsidiaries and the Company’s and its Subsidiaries’ use of any
Intellectual Property Rights or Confidential Information owned by a third party, and, to the Company’s Knowledge, there is
no valid basis for the same.

 

    9

     

    

 

4.16        
Litigation. With such exceptions that, individually or in the aggregate, are not reasonably expected to have a Material
Adverse Effect, there is no litigation or governmental proceeding pending or, to the Company’s Knowledge, threatened, against
the Company or any of its Subsidiaries or affecting any of the properties or assets of the Company or any of its Subsidiaries.
Neither the Company nor any Subsidiary is in default with respect to any order, writ, injunction, decree, ruling or decision of
any court, commission, board or other government agency that is expressly applicable to the Company or any Subsidiary or any of
their assets or property.

 

4.17        
Insurance Coverage. The Company and each Subsidiary maintains insurance coverage that is customary for comparably
situated companies for the business being conducted and properties owned or leased by the Company and each Subsidiary. All such
insurance is fully in force, except where the failure to be in full force has not had and would not, individually or in the aggregate,
be reasonably expected to have a Material Adverse Effect

 

4.18        
Compliance with Nasdaq Continued Listing Requirements. Except as described in the SEC Filings, the Company is in
compliance with applicable Nasdaq continued listing requirements. Except as described in the SEC Filings, there are no proceedings
pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock
on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any basis for, the delisting
of the Common Stock from Nasdaq. The issuance by the Company of the Shares shall not have the effect of delisting or suspending
the Common Stock from Nasdaq.

 

4.19        
Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents,
any valid right, interest or claim against or upon the Company, any Subsidiary or an Investor for any commission, fee or other
compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company, other than as
described in Schedule 4.19. The Company shall pay, and hold each Investor harmless against, any liability, loss or
expense (including, without limitation, attorney’s fees and out-of-pocket expenses) arising in connection with any such claim.

 

4.20        
Securities Law Compliance. Assuming the accuracy of the representations and warranties of the Investors set forth
in Section 5 hereof, the offer, sale and issuance of the Shares pursuant to this Agreement will be exempt from the
registration requirements of the 1933 Act. The Company has not, in connection with the transactions contemplated by this Agreement,
engaged in: (a) any form of general solicitation or general advertising (as those terms are used within the meaning of Rule
502(c) promulgated under the 1933 Act); (b) any action involving a “public offering” within the meaning of
Section 4(a)(2) of the 1933 Act; or (c) any action that would require the registration under the 1933 Act of the offer
and sale of the Shares pursuant to this Agreement. As used herein, the terms “offer” and “sale” have the
meanings specified in Section 2(a)(3) of the 1933 Act. Without limiting the generality of the foregoing, none of the Company,
its Subsidiaries or any of their Affiliates, nor any Person acting on their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the
issuance of any of the Shares under the 1933 Act, whether through integration with prior offerings or otherwise, or cause this
offering of the Shares to require approval of stockholders of the Company for purposes of the 1933 Act or any applicable stockholder
approval provisions, including, without limitation, under the rules and regulations of any exchange or automated quotation system
on which any of the securities of the Company are listed or designated for quotation. None of the Company, its Subsidiaries, their
Affiliates nor any Person acting on their behalf will take any action or steps referred to in the preceding sentence that would
require registration of the issuance of any of the Shares under the 1933 Act or cause the offering of any of the Shares to be integrated
with other offerings for purposes of any such applicable stockholder approval provisions.

 

    10

     

    

 

4.21        
Transactions with Affiliates. Except as disclosed in the SEC Filings or as disclosed on Schedule 4.21,
none of the officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is
presently a party to any transaction with the Company or any Subsidiary (other than as holders of stock options and/or warrants,
and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the
furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments
to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee or partner.

 

4.22        
Internal Controls. The Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002, as
amended, and any and all applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof
and that are currently applicable to the Company. The Company and the Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general
or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain accountability for assets, (iii) access to assets or incurrence of liabilities is permitted only
in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets and
liabilities is compared with the existing assets and liabilities at reasonable intervals and appropriate action is taken with respect
to any differences. The Company has established and maintains disclosure controls and procedures (as such term is defined in Rule
13a-15 and 15d-15 under the 1934 Act). Such disclosure controls and procedures are designed to provide reasonable assurance that
material information relating to the Company, including its Subsidiaries, that is required to be disclosed by the Company in the
reports that it furnishes or files under the 1934 Act is reported within the time periods specified in the rules and forms of the
SEC and that such material information is communicated to the Company’s management to allow timely decisions regarding required
disclosure. To the Company’s Knowledge, there is no (i) significant deficiency in the design or operation of internal controls
which could adversely affect the Company’s or any of its Subsidiary’s ability to record, process, summarize and report
financial data or any material weaknesses in internal controls; or (ii) fraud, whether or not material, that involves management
or other employees who have a significant role in the Company’s or any of its Subsidiary’s internal controls.

 

4.23        
Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or
any of its Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company
in its 1934 Act filings and is not so disclosed or that otherwise would be reasonably likely to have a Material Adverse Effect.

 

    11

     

    

 

4.24         
Investment Company. Neither the Company nor any of its Subsidiaries is, and immediately after giving effect to the
sale of the Shares in accordance with this Agreement and the application of the proceeds thereof will not be required to be registered
as, an “investment company” or a company “controlled” by an “investment company,” within the
meaning of the Investment Company Act of 1940, as amended.

 

4.25         
Application of Takeover Protections. The Company and its board of directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, interested shareholder, business combination, poison pill (including,
without limitation, any distribution under a rights agreement) or other similar anti-takeover provision under the Certificate of
Incorporation, Bylaws or other organizational documents or the laws of the jurisdiction of its formation (including, without limitation,
Section 203 of the Delaware General Corporation Law) which is or could become applicable to any Investor as a result of the transactions
contemplated by this Agreement, including, without limitation, the Company’s issuance of the Shares and any Investor’s
ownership of the Shares.

 

4.26         
Solvency. Neither the Company nor any of its Subsidiaries has taken any steps to seek protection pursuant to any
law or statute relating to bankruptcy, insolvency, reorganization, receivership, liquidation or winding up, nor does the Company
or any Subsidiary have any knowledge or reason to believe that any of their respective creditors intend to initiate involuntary
bankruptcy proceedings or any Knowledge of any fact which would reasonably lead a creditor to do so. The Company and its Subsidiaries,
individually and on a consolidated basis, are not as of the date hereof, and after giving effect to the transactions contemplated
hereby to occur at the Closing, will not be Insolvent.

 

4.27         
Conduct of Business. Neither the Company nor any of its Subsidiaries is in violation of any term of or in default
under its Certificate of Incorporation, any certificate of designations, preferences or rights of any other outstanding series
of preferred stock of the Company or any of its Subsidiaries or Bylaws or their organizational charter, certificate of formation
or certificate of incorporation or bylaws, respectively. Neither the Company nor any of its Subsidiaries is in violation of any
judgment, decree or order or any statute, ordinance, rule or regulation applicable to the Company or any of its Subsidiaries, and
neither the Company nor any of its Subsidiaries will conduct its business in violation of any of the foregoing, except in all cases
for possible violations which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

4.28         
Compliance with Anti-Money Laundering Laws. The operations of the Company and
its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements
and all other applicable U.S. and non-U.S. anti-money laundering laws and regulations,
including, but not limited to, those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the USA Patriot
Act of 2001 and the applicable money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder
and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,
the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Anti-Money Laundering
Laws is pending or, to the knowledge of the Company, threatened.

 

    12

     

    

 

4.29         
No Conflicts with Sanctions Laws. Neither the Company nor any of its Subsidiaries,
nor to the Company’s Knowledge, any director, officer, employee, agent, Affiliate or other person associated with or acting
on behalf of the Company or any of its Subsidiaries or Affiliates is, or is directly or indirectly owned or controlled by, a Person
that is currently the subject or the target of any sanctions administered or enforced by the U.S. government (including, without
limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S.
Departments of State or Commerce and including, without limitation, the designation as a “specially designated national”
or “blocked person”), the United Nations Security Council (“UNSC”), the European Union, Her Majesty’s
Treasury (“HMT”) or any other relevant sanctions authority (collectively, “Sanctions”), nor
is the Company or any of its Subsidiaries located, organized or resident in a country or territory that is the subject or target
of a comprehensive embargo or Sanctions prohibiting trade with the country or territory, including, without limitation, Cuba, Iran,
North Korea, Sudan and Syria (each, a “Sanctioned Country”); no action of the Company or any of its Subsidiaries
in connection with (i) the execution, delivery and performance of this Agreement and the other Transaction Documents, (ii) the
issuance and sale of the Shares or (iii) the direct or indirect use of proceeds from the Shares or the consummation of any other
transaction contemplated hereby or by the other Transaction Documents or the fulfillment of the terms hereof or thereof, will result
in the proceeds of the transactions contemplated hereby and by the other Transaction Documents being used, or loaned, contributed
or otherwise made available, directly or indirectly, to any Subsidiary, joint venture
partner or other person or entity, for the purpose of (i) unlawfully funding or facilitating any activities of or business with
any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) unlawfully funding or
facilitating any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation
by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of
Sanctions. For the past five years, or since the Company’s or such subsidiary’s formation, whichever is more recent,
the Company and its Subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country.

 

4.30         
Anti-Bribery. Neither the Company nor any of its Subsidiaries, nor to the Company’s
Knowledge, any director, officer, employee, agent, Affiliate or other person associated with or acting on behalf of the Company,
or any of its Subsidiaries or Affiliates, has (i) used any funds for any unlawful
contribution, gift, entertainment or other unlawful expense relating to political activity, (ii) made any direct or indirect unlawful
payment to any foreign or domestic government official or employee, to any employee or agent of a private entity with which the
Company does or seeks to do business (a “Private Sector Counterparty”) or to foreign or domestic political parties
or campaigns from corporate funds, (iii) violated or is in violation of any provision of any applicable law or regulation implementing
the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions or any applicable provision
of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), the U.K Bribery Act 2010, or any
other similar law of any other jurisdiction in which the Company operates its business, including, in each case, the rules and
regulations thereunder, (iv) taken, is currently taking or will take any action in furtherance of an offer, payment, gift or anything
else of value, directly or indirectly, to any person while knowing that all or some portion of the money or value will be offered,
given or promised to anyone to improperly influence official action, to obtain or retain business or otherwise to secure any improper
advantage or (v) otherwise made any bribe, rebate, payoff, influence payment, unlawful kickback or other unlawful payment; the
Company and each of its respective Subsidiaries has instituted and has maintained, and will continue to maintain, policies and
procedures reasonably designed to promote and achieve compliance with the laws referred to in (iii) above and with this representation
and warranty; and none of the Company, nor any of its Subsidiaries or Affiliates will directly or indirectly use the proceeds of
the sale of the Shares or lend, contribute or otherwise make available such proceeds to any
subsidiary, Affiliate, joint venture partner or other person or entity for the purpose of financing or facilitating any activity
that would violate the laws and regulations referred to in (iii) above.

 

    13

     

    

 

4.31         
Shell Company Status. The Company is not, and has never been, an issuer identified in, or subject to, Rule 144(i).

 

4.32         
No Disqualification Events. With respect to Shares to be offered and sold hereunder in reliance on Rule 506(b) under
the 1933 Act (“Regulation D Securities”), none of the Company, any of its predecessors, any affiliated issuer,
any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of
20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the 1933 Act) connected with the Company in any capacity at the time of sale (each,
an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject to any of
the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable
care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent
applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Investors a copy of any disclosures provided
thereunder.

 

4.33         
Manipulation of Price. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result, or that could reasonably be expected to cause or result, in the stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Shares, (ii) other than
the Persons set forth on Schedule 4.19, sold, bid for, purchased, or paid any compensation for soliciting purchases of,
any of the Shares, or (iii) other than the Persons set forth on Schedule 4.19, paid or agreed to pay to any Person any compensation
for soliciting another to purchase any other securities of the Company.

 

5.            Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly, represents
and warrants to the Company that:

 

5.1            Organization and Existence. Such Investor is a validly existing corporation, limited partnership or limited liability
company and has all requisite corporate, partnership or limited liability company power and authority to purchase the Shares pursuant
to this Agreement.

 

    14

     

    

 

5.2           Authorization. The execution, delivery and performance by such Investor of the Transaction Documents to which such
Investor is a party have been duly authorized and, assuming due execution and delivery thereof by each of the other parties thereto,
each will constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in accordance
with their respective terms, except as such enforceability may be limited by applicable laws relating to bankruptcy, insolvency,
reorganization, moratorium or other similar legal requirement relating to or affecting creditors’ rights generally and except
as such enforceability is subject to general principles of equity (regardless of whether enforceability is considered in a proceeding
in equity or at law).

 

5.3           Consents. No consent, approval, license or authorization of, or designation, declaration or filing with, any court
or governmental authority is or will be required on the part of such Investor in connection with the execution, delivery and performance
by such Investor of the Transaction Documents to which such Investor is a party, except for: (a) those which have already
been made or granted; (b) the filing with the SEC of any filing required pursuant to Section 13 and/or Section 16 of the 1934
Act; and (c) those where the failure to obtain such consent, approval or license would not have a material adverse effect
on the ability of the Investors to perform their obligations hereunder.

 

5.4           Purchase Entirely for Own Account. The Shares to be received by such Investor hereunder will be acquired for such
Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in
violation of the 1933 Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise
dispose of all or any part of such Shares in compliance with applicable federal and state securities laws. Nothing contained herein
shall be deemed a representation or warranty by such Investor to hold the Shares for any period of time. Neither such Investor
nor any Affiliate of such Investors is a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business
that would require it to be so registered.

 

5.5           Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment
in the Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits
and risks of the investment contemplated hereby.

 

5.6           Disclosure of Information. Such Investor has had an opportunity to receive all information related to the Company
requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms
and conditions of the offering of the Shares. Such Investor acknowledges receipt of copies of the SEC Filings. Neither such inquiries
nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect such Investor’s
right to rely on the Company’s representations and warranties contained in this Agreement.

 

    15

     

    

  

5.7           Restricted Securities. Such Investor understands that the are characterized as “restricted securities”
under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public
offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933
Act only in certain limited circumstances.

 

5.8           Legends. It is understood that the book-entry notations evidencing the Shares shall bear a restrictive legend in
substantially the following form (in addition to any legend required under applicable state securities laws), until such time as
they are not required under Section 7.5 or applicable law:

 

“THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED
UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH
SECURITIES MAY BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

“THE SECURITIES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO TRANSFER AND OTHER RESTRICTIONS SET FORTH IN A SECURITIES PURCHASE AGREEMENT, DATED
AS OF NOVEMBER 10, 2017, COPIES OF WHICH ARE ON FILE WITH THE SECRETARY OF THE COMPANY AT THE COMPANY’S PRINCIPAL EXECUTIVE
OFFICES.”

 

5.9          
Accredited Investor. Such Investor is an “accredited investor” as defined in Rule 501(a) of Regulation
D, as amended, under the 1933 Act.

 

5.10        
No General Solicitation. Such Investor did not learn of the investment in the Shares as a result of any general advertising
or, to such Investor’s knowledge, general solicitation.

 

5.11        
Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents,
any valid right, interest or claim against or upon the Company, any Subsidiary or an Investor for any commission, fee or other
compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor.

 

    16

     

    

 

5.12       
Prohibited Transactions. Since the earlier of (a) such time as such Investor was first contacted by the Company
or any other Person acting on behalf of the Company regarding the transactions contemplated hereby or (b) thirty (30) days
prior to the date hereof, neither such Investor nor any Affiliate of such Investor which (x) had knowledge of the transactions
contemplated hereby, (y) has or shares discretion relating to such Investor’s investments or trading or information concerning
such Investor’s investments, including in respect of the Shares, or (z) is subject to such Investor’s review or input
concerning such Affiliate’s investments or trading (collectively, “Trading Affiliates”) has, directly
or indirectly, (A) effected or agreed to effect any transactions in the securities of the Company or involving the Company’s
securities while in possession of any material nonpublic information of the Company disclosed to such Investor in connection with
such Investor’s decision-making with respect to their acquisition of the Shares or (B) effected or agreed to effect any short
sale (as defined in Rule 200 of Regulation SHO under the 1934 Act (“Short Sales”)), whether or not against the
box, established any “put equivalent position” (as defined in Rule 16a-1(h) under the 1934 Act) with respect to the
Common Stock, granted any other right (including, without limitation, any put or call option) with respect to the Common Stock
or with respect to any security that includes, relates to or derived any significant part of its value from the Common Stock or
otherwise sought to hedge its position in the Shares (each, a “Prohibited Transaction”). Prior to the earliest
to occur of (i) the termination of this Agreement, (ii) the Effective Date, (iii) the Effectiveness Deadline and (iv) the
date the Shares may be sold pursuant to Rule 144, each Investor shall not, and shall cause its Trading Affiliates not to, engage,
directly or indirectly, in a Prohibited Transaction. Each Investor understands and acknowledges that the SEC currently takes the
position that covering a short position established prior to effectiveness of a resale registration statement with shares included
in such registration statement would be a violation of Section 5 of the 1933 Act, as set forth in the SEC’s Compliance
and Disclosure Interpretation 239.10.

 

5.13       
Trading Price. Such Investor acknowledges that while the Per Share Price has been determined through negotiations
with third-party unaffiliated Investors, the Company’s stock is thinly traded, and accordingly the trading price of the Company’s
stock may not accurately reflect the current value of the Company.

 

6.           
Conditions to Closing.

 

6.1          Conditions to the Investors’ Obligations. The obligations of the Investors to purchase the Shares at the Closing
is subject to the satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived in whole
or in part by the Investors:

 

(a)          The representations and warranties made by the Company in Section 4 hereof qualified as to materiality shall
be true and correct at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly
speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date,
and, the representations and warranties made by the Company in Section 4 hereof not qualified as to materiality shall
be true and correct in all material respects at all times prior to and on the Closing Date, except to the extent any such representation
or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in
all material respects as of such earlier date. Such Investor shall have received a certificate, executed by the Chief Executive
Officer of the Company, dated as of the Closing Date, to the foregoing effect.

 

    17

     

    

 

(b)          The Company shall have performed in all material respects all obligations and covenants herein required to be performed
by it on or prior to the Closing Date.

 

(c)          The Company shall have issued to each Investor book-entry shares representing the number of Shares set forth opposite such
Investor’s name in the Schedule of Investors.

 

(d)          The Company shall have duly executed and delivered the Registration Rights Agreement.

 

(e)          The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares
on the Nasdaq Capital Market, a copy of which shall have been provided to the Investors.

 

(f)           The Company shall have received gross proceeds from the sale of the Shares as contemplated hereby of the Purchase Price.

 

(g)          The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing
Date, certifying the resolutions adopted by the Board of Directors of the Company, or any authorized committee thereof, approving
the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Shares, certifying
the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority
of persons signing the Transaction Documents and related documents on behalf of the Company.

 

(h)          The Investors shall have received an opinion from Orrick, Herrington & Sutcliffe LLP, the Company’s counsel, dated
as of the Closing Date, in form and substance reasonably acceptable to the Investors and addressing such legal matters as the Investors
may reasonably request.

 

(i)           No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory
body with respect to public trading in the Common Stock.

 

(j)           The Company shall have consummated the TCV Exchange.

 

(k)          The Company shall have delivered to such Investor a certificate evidencing the formation and good standing of the Company
and each of its Subsidiaries listed on Exhibit C hereto in such entity’s jurisdiction of formation issued by the Secretary
of State (or comparable office) of such jurisdiction, as of a date within ten (10) days of the Closing Date.

 

(l)           The Company shall have delivered to such Investor a certificate evidencing the Company’s qualification as a foreign
corporation and good standing issued by the Secretary of State (or comparable office) of each jurisdiction in which the Company
conducts business and is required to so qualify, as of a date within ten (10) days of the Closing Date.

 

    18

     

    

 

(m)        The Company shall have obtained all governmental, regulatory or third party consents and approvals, including, without limitation,
from Nasdaq, if any, necessary for the sale of the Shares.

 

6.2         
Conditions to Obligations of the Company. The Company’s obligation to sell and issue the Shares at the Closing
is subject to the satisfaction on or prior to the Closing Date of the following conditions, any of which may be waived in whole
or in part by the Company:

 

(a)          The representations and warranties made by the Investors in Section 5 hereof, other than the representations
and warranties contained in Sections 5.4, 5.5, 5.6, 5.7, 5.8, 5.9 and 5.10
(the “Investment Representations”), shall be true and correct in all material respects when made, and shall
be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and
as of said date. The Investment Representations shall be true and correct in all respects when made, and shall be true and correct
in all respects on the Closing Date with the same force and effect as if they had been made on and as of said date.

 

(b)          The Investors shall have performed in all material respects all obligations and covenants herein required to be performed
by them on or prior to the Closing Date.

 

(c)          The Investors shall have executed and delivered the Registration Rights Agreement.

 

(d)         The Investors shall have delivered the Purchase Price to the Company.

 

6.3         
Termination of Obligations to Effect Closing; Effects.

 

(a)         
The obligations of the Company, on the one hand, and any Investor, on the other hand, to effect the Closing shall terminate
as follows:

 

(i)         Upon the mutual written consent of the Company and such Investor;

 

(ii)        By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and
shall not have been waived by the Company;

 

(iii)       By such Investor if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and
shall not have been waived by such Investor; or

 

(iv)       By either the Company or the Investors if the Closing has not occurred on or prior to November 17, 2017;

 

    19

     

    

 

provided,
however, that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect the
Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement
or the other Transaction Documents if such breach has resulted in the circumstances giving rise to such party’s seeking to
terminate its obligation to effect the Closing.

 

(b)          
Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party
of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel
specific performance by any other party of its obligations under this Agreement or the other Transaction Documents.

 

7.            Covenants and Agreements of the Parties.

 

7.1          Form D and Blue Sky. The Company agrees to file a Form D with respect to the Shares as required under Regulation
D and to provide a copy thereof to each Investor promptly after such filing. The Company shall, on or before the Closing Date,
take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Shares
for sale to the Investors at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws
of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such
action so taken to the Investors on or prior to the Closing Date. The Company shall make all filings and reports relating to the
offer and sale of the Shares required under applicable securities or “Blue Sky” laws of the states of the United States
following the Closing Date.

 

7.2          Reporting Status. Until the earlier of (A) six months after such date as all of the Registrable Securities (as defined
in the Registration Rights Agreement) may be sold without restriction by the holders thereof pursuant to Rule 144 or any other
rule of similar effect and without the requirement for the Company to be in compliance with Rule 144(c)(1) and (B) such date as
all of the Registrable Securities shall have been resold pursuant to a Registration Statement, Rule 144 or otherwise in a transaction
in which the transferee receives freely tradable shares (the “Reporting Period”), the Company shall timely file
all reports required to be filed with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status as an issuer
required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would no longer require
or otherwise permit such termination. The Company hereby covenants and agrees to use commercially reasonable efforts to maintain
its eligibility to register the Shares for resale by the Investors on Form S-3. The failure to file a report in a timely manner
shall not be deemed to be a breach of this Section 7.2 so long as the Investors are able to sell their Shares without restriction
or interruption under an effective Registration Statement filed with the SEC by the Company.

 

7.3          Notice of Disqualification Events. The Company will notify the Investors in writing, prior to the Closing Date of
(i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become
a Disqualification Event relating to any Issuer Covered Person.

 

    20

     

    

 

7.4          Listing. The Company will use reasonable best efforts to continue the listing and trading of its Common Stock and
to effect and maintain the listing of the Shares on Nasdaq.

 

7.5          Transfer; Removal of Legends. The Shares may not be offered for sale, sold, assigned or transferred unless (A) subsequently
registered for resale under the 1933 Act as contemplated by the Registration Rights Agreement, (B) such Investor shall have delivered
to the Company an opinion of counsel, in a reasonably acceptable form, to the effect that such Shares to be sold, assigned or transferred
may be sold, assigned or transferred pursuant to an exemption from such registration, or (C) such Investor provides the Company
with reasonable assurance that such Shares can be sold, assigned or transferred pursuant to Rule 144. The Company shall, or shall
cause the Transfer Agent to, issue replacement book-entry notations representing the Shares sold or disposed of without restrictive
legends, or, at the election of such Investor, by delivery via the Deposit/Withdrawal at Custodian system of The Depository Trust
Company (“DTC”), upon the earlier of (i) registration for resale under the 1933 Act at which time the Company
shall cause its counsel to deliver to the Transfer Agent one or more blanket opinions to the effect that the removal of such legends
in such circumstances may be effected under the 1933 Act or (ii) the Shares becoming freely tradable by a non-Affiliate pursuant
to Rule 144 and such non-Affiliate delivers to the Company a customary representation that the Shares may be sold pursuant
to Rule 144.

 

7.6          Transfer Restrictions.

 

(a)           Notwithstanding anything to the contrary this Agreement, the Investors will not at any time directly or indirectly transfer
or assign any Shares, or any interest therein, knowingly to (i) any person or entity that directly competes with the Company in
one or more material aspects of the Company's business, as determined in good faith by the Board of Directors of the Company in
its reasonable discretion, or (ii) any member of a “group” (as defined in Section 13(d)(3) of the 1934 Act) which has
filed a statement of beneficial ownership report on Schedule 13D with the SEC or otherwise expressed an interest in acquiring the
Company and any such transfer or assignment shall be null and void unless otherwise approved in advance by the Company; provided,
however, that the foregoing shall not restrict any such transfer into the public market pursuant to a bona fide registered
public offering or any open market transaction or any transfer made in connection with the sale of all or substantially all of
the capital stock, assets or business of the Company, by merger, consolidation, sale of assets or otherwise; provided, further,
that the foregoing shall not restrict the ability of the Investors to vote their shares or otherwise execute proxies and/or consents
pertaining thereto.

 

(b)           During the Standstill Period, the Company must be, within a reasonable time after a transfer otherwise permitted hereunder,
furnished with written notice of such transfer, including the name and address of such transferee, and no such transfer may be
made unless such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and
conditions of this Agreement, including the provisions of Section 7.9.

 

    21

     

    

 

7.7         Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated
hereby shall be issued by the Company or the Investors without the prior consent of the Company (in the case of a release or announcement
by the Investors) or the Investors (in the case of a release or announcement by the Company) (which consents shall not be unreasonably
withheld), except as such release or announcement may be required by law or the applicable rules or regulations of any securities
exchange, securities regulator or securities market, in which case the Company or the Investors, as the case may be, shall (except
for filings required to be made by any Investor pursuant to Section 13 and/or Section 16 of the 1934 Act) allow the Investors or
the Company, as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release
or announcement in advance of such issuance. By 9:30 a.m. (New York City time) on the trading day immediately following the date
hereof, the Company shall issue a press release (the “Press Release”) disclosing all material terms of the transactions
contemplated hereby and the other Transaction Documents and the consummation of the transactions contemplated by the Transaction
Documents. No later than the fourth trading day following the date hereof, the Company will file a Current Report on Form 8-K describing
the terms of the Transaction Documents (and including as exhibits to such Current Report on Form 8-K the Transaction Documents
with any schedules attached thereto).

 

7.8        
Confidentiality; Insider Trading Policy.

 

(a)            Each Investor, severally and not jointly with the other Investors, covenants that until the earlier of (x) the issuance
of the Press Release and (y) the first trading day immediately following the date of this Agreement, such Investor will, and will
use its commercially reasonable efforts to cause its Affiliates to, maintain the confidentiality of the existence and terms of
this transaction and the information included in the Transaction Documents and Disclosure Schedules.

 

(b)            The Investors will, and will cause their Affiliates to, maintain the confidentiality of all material nonpublic information
of the Company disclosed to any of them by or on behalf of the Investor Designee (in his or her capacity as a member of the Board).
The Investor Designee shall further agree to comply with the insider trading compliance program of the Company applicable to outside
directors including, but not limited to, trade pre-clearance requirements and trading blackout periods as may be in effect from
time to time. In addition, each Investor hereby acknowledges that such Investor is aware that United States securities laws prohibit
any person who has received from an issuer material nonpublic information concerning the issuer from communicating such information
to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell the
securities of such issuer, make investment recommendations based on such material nonpublic information or otherwise affect the
trading price of such issuer’s securities.

 

7.9        
Standstill. Each Investor agrees that, from the date hereof until June 30, 2019 (the “Standstill Period”),
it will not, and it will cause each of its Affiliates, directors and officers not to, directly or indirectly, without the prior
written consent of the Company’s Board of Directors (for which the Investor Designee shall not be deemed “disinterested”):
(i) make, or in any way participate in, directly or indirectly, any “solicitation” of “proxies” (as such
terms are used in the rules of the SEC) to vote, or seek to advise or influence any person or entity (other than an Affiliate of
the Investor) with respect to the voting of, any debt or equity securities of the Company, including relating to the election of
directors with respect to the Company, (ii) make any public announcement with respect to, or submit a proposal for, or offer of
(with or without conditions) any extraordinary transaction involving the Company or its debt, equity securities or assets, (iii)
form, join or in any way participate in a “group” (as defined in Section 13(d)(3) of the Exchange Act) in connection
with any of the foregoing or (iv) request the Company or any of its representatives, directly or indirectly, to amend or waive
any provision of this Section 7.9 other than through non-public communications with the Company that would not be reasonably
determined to trigger public disclosure obligations for any party; provided, however, that the restrictions set forth
in this Section 7.9 shall terminate and be of no further force and effect if the Company enters into a definitive agreement
with respect to, or publicly announces that it plans to enter into, a transaction involving all or a controlling portion of the
Company’s equity securities or all or substantially all of the Company’s assets (whether by merger, consolidation,
business combination, tender or exchange offer, recapitalization, restructuring, sale, equity issuance or otherwise).

 

    22

     

    

 

7.10        
Board Designee. For so long as the Investors collectively beneficially own one hundred percent (100%) of the Shares
and five percent (5%) or more of the total issued and outstanding shares of the Company, the Investors shall have the right to
designate one member of the Board of Directors of the Company (the “Investor Designee”) (and to fill the vacancy
of such member in the event of the resignation, death or removal of such member or failure of such member to be elected); provided
that such Investor Designee shall qualify as an “independent director” under the listing standards of Nasdaq (or such
other exchange on which the Company’s Common Stock may be listed) and shall be required to complete a questionnaire in the
same form as has been executed by all other directors for the Company. The initial Investor Designee designated by the Investors
shall be Mr. Kevin M. Rendino. Simultaneous with the Closing, the Company shall increase the size of its Board of Directors by
one, fill the resulting vacancy with the initial Investor Designee in accordance with the Company’s Bylaws and appoint such
Investor Designee as a Class I director. Unless otherwise agreed to by the Company’s Board of Directors, the Investor Designee
shall not be appointed to or otherwise gain membership on any of the committees of the Board of Directors. Thereafter, so long
as the Investor Designee is reasonably acceptable to the Company’s Nominating and Corporate Governance Committee (for the
avoidance of doubt, it being understood that Mr. Kevin M. Rendino is reasonably acceptable to such committee), the Company shall
(i) nominate and recommend in the Company’s proxy statement the Investor Designee as a Class I director of the Company’s
Board of Directors at each meeting of stockholders of the Company where the class of which the Investor Designee is a member is
up for election, which for the avoidance of doubt will be the 2018 annual meeting of stockholders of the Company, and (ii) in
the event that the Investor Designee shall resign or be removed as a director for any reason during the period that this Section 7.10
is in effect, fill the vacancy resulting thereby with an Investor Designee. The Company shall provide all rights and benefits of
indemnity to each Investor Designee as are provided to other outside directors of the Company. In the event the Company’s
Nominating and Corporate Governance Committee does not in good faith approve a particular individual as the Investor Designee for
the slate of Class I directors or filling of a vacancy as a result of the process described in this Section 7.10, then
the Investors shall designate a different Investor Designee, whom shall be subject to the same review and approval process and
whose nomination will not be unreasonably withheld. For the avoidance of doubt, the Company hereby affirms that the initial Investor
Designee identified above satisfies such qualifications. At such time that the Investors no longer collectively beneficially own
all of the Shares and five percent (5%) or more of the total issued and outstanding shares of the Company, or any Investor distributes
any of such shares to one or more of its investors, the Investors’ right to designate the Investor Designee shall immediately
terminate and the Investors shall cause the then-serving Investor Designee to promptly resign from the Company’s Board of
Directors. The Investors agree to give prompt notice to the Company if they cease to collectively beneficially own any of the Shares.

 

    23

     

    

 

7.11        
Registration of TCV Shares. In accordance with Section 2(a) of the Registration Rights Agreement, the Investors hereby
consent to the inclusion of the TCV Shares in the initial Registration Statement to be prepared and filed by the Company thereby.

 

8.            Miscellaneous.

 

8.1           Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the
Closing of the transactions contemplated by this Agreement.

 

8.2           Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of
the Company or the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its duties
hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Shares in a transaction complying
with applicable securities laws without the prior written consent of the Company or the other Investors. The provisions of this
Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Without
limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange or
similar business combination transaction in which the Common Stock is converted into the equity securities of another Person, from
and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the
obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and the term “Shares”
shall be deemed to refer to the securities received by the Investors in connection with such transaction. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns
any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

8.3           Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument and shall become effective when counterparts have been signed
by each party and delivered to the other parties. In the event that any signature is delivered by facsimile transmission, or by
e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page were
an original thereof.

 

8.4           Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to
be considered in construing or interpreting this Agreement.

 

    24

     

    

 

8.5          Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing
and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be
deemed given upon such delivery, (ii) if given by facsimile (or like transmission), then such notice shall be deemed given
upon receipt of confirmation of complete transmittal, (iii) if given by electronic mail during normal business hours of the
recipient, and if not sent during normal business hours, then on the recipient’s next business day, (iv) if given by
mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three
days after such notice is deposited in first class mail, postage prepaid, and (v) if given by an internationally recognized
overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier. All notices shall
be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten
days’ advance written notice to the other party:

 

If to the Company:

 

TheStreet, Inc.

14 Wall Street, 15th Floor

New York, New York 10005

Attention: Heather Mars, General Counsel

Facsimile: (212) 321-5015

Email: heather.mars@thestreet.com

 

With a copy to (which shall not constitute notice to
the Company):

 

Orrick, Herrington & Sutcliffe LLP

405 Howard Street

San Francisco, California 94105

Attention: Karen Dempsey

Facsimile: (415) 773-5759

Email: kdempsey@orrick.com

 

If to an Investor:

 

180 Degree Capital Corp.

7 N. Willow Street, Suite 4B

Montclair, New Jersey 07042

Attention: Daniel B. Wolfe

Facsimile: 973-746-4508

Email: Daniel@180degreecapital.com

 

With a copy to (which shall not constitute notice to
the Investors):

 

Schulte Roth & Zabel LLP

1152 Fifteenth Street, NW, Suite 850

Washington, DC 20005

Attention: John J. Mahon

Facsimile: (202) 730-4520

Email: John.Mahon@srz.com

 

    25

     

    

 

8.6           Expenses. Whether or not the Closing shall occur, all fees, costs and expenses incurred in connection with this Agreement
and the transactions contemplated hereby, including accounting and legal fees shall be paid by the party incurring such expenses,
except that, upon consummation of the transactions contemplated hereby, the Company shall pay up to $50,000 of the reasonable and
documented out-of-pocket fees and expenses incurred by the Investors, including, without limitation, the reasonable and documented
fees and expenses of counsel for the Investors.

 

8.7           Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement
may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent
of the Company and the Investors. Any such amendment or waiver effected in accordance with this paragraph shall be binding upon
each holder of any securities purchased under this Agreement at the time outstanding (including securities into which such securities
have been converted or exchanged or for which such securities have been exercised) and each future holder of all such securities.

 

8.8           Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions
hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law,
and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in
any other jurisdiction so long as this Agreement as so modified continues to express, without material change, the original intentions
of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in
question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization
of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace
the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible
to that of the prohibited, invalid or unenforceable provision(s). To the extent permitted by applicable law and subject to the
foregoing, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any
respect.

 

8.9           Entire Agreement. This Agreement, including the Exhibits and the Disclosure Schedules, and the other Transaction
Documents constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and
thereof.

 

    26

     

    

 

8.10         Further Assurances. The parties shall execute and deliver all such further instruments and documents and take all
such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment
of the agreements herein contained.

 

8.11         Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed
in accordance with, the internal laws of the State of New York applicable to contracts made in and to be performed in that state,
without regard to the conflicts of law principles thereof, to the extent such principles would require or permit the application
of the laws of another jurisdiction. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts
of the State of New York located in New York County and the United States District Court for the Southern District of New York
for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated
hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in
the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably
consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.
Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such
courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in
an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT
TO OR ARISING OUT OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY
AS TO THIS WAIVER.

 

    27

     

    

 

8.12        
Indemnification. In consideration of each Investor’s execution and delivery of the Transaction Documents and
acquiring the Shares thereunder and in addition to all of the Company’s other obligations under the Transaction Documents,
the Company shall defend, protect, indemnify and hold harmless each Investor and each other holder of the Shares and all of their
stockholders, partners, members, officers, directors, employees and direct or indirect investors and any of the foregoing Persons’
agents or other representatives (including, without limitation, those retained in connection with the transactions contemplated
by this Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action,
suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether
any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’
fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising
out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in the Transaction
Documents or any other certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement
or obligation of the Company contained in the Transaction Documents or any other certificate, instrument or document contemplated
hereby or thereby or (c) any cause of action, suit or claim brought or made against such Indemnitee by a third party (including
for these purposes a derivative action brought on behalf of the Company) and arising out of or resulting from (i) the execution,
delivery, performance or enforcement of the Transaction Documents or any other certificate, instrument or document contemplated
hereby or thereby, other than claims for indemnification within the scope of Section 6 of the Registration Rights Agreement, (ii)
any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the
Shares, or (iii) the status of such Investor or holder of the Shares as an investor in the Company pursuant to the transactions
contemplated by the Transaction Documents, except, in each case, with respect to any Indemnified Liabilities that resulted solely
from any Indemnitee’s gross negligence, willful misconduct or fraud. To the extent that the foregoing undertaking by the
Company may be unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of
each of the Indemnified Liabilities that is permissible under applicable law. Except as otherwise set forth herein, the mechanics
and procedures with respect to the rights and obligations under this Section 8.12 shall be the same as those set forth in
Section 6 of the Registration Rights Agreement.

 

[signature page follows]

 

    28

     

    

 

IN WITNESS WHEREOF,
the parties have executed this Securities Purchase Agreement or caused their duly authorized officers to execute this Securities
Purchase Agreement as of the date first above written.

	 	 	 	 
	The Company:	THESTREET, INC.
	 	 	 	 
	 	By:	 	/s/ David A. Callaway
	 	Name:	David A. Callaway
	 	Title:	Chief Executive Officer

 

[Signature Page to
TheStreet, Inc. Securities Purchase Agreement]

 

     

     

    

 

	The Investors:	180 Degree Capital Corp.
	 	 	 	 
	 	By:	 	/s/ Daniel Wolfe
	 	Name:	Daniel Wolfe
	 	Title:	President
	 	 	 	 
	 	TheStreet SPV Series, a limited liability company series of 180 Degree Capital Management, LLC
	 	 	 	 
	 	By:	 	/s/ Daniel Wolfe
	 	Name:	Daniel Wolfe
	 	Title:	President, 180 Degree Capital Corp.
	 	 	 	Managing Member

 

[Signature Page to
TheStreet, Inc. Securities Purchase Agreement]

 

     

     

    

 

Exhibit A

 

Schedule of Investors

 

	Investor	 	Number of
 Shares	 	 	Aggregate
 Purchase Price	 
	180 Degree Capital Corp.	 	 	3,636,363	 	 	$	3,999,999.30	 
	TheStreet SPV Series, a limited liability company series of 180 Degree Capital Management, LLC	 	 	3,500,000	 	 	$	3,850,000.00	 
	Total	 	 	7,136,363	 	 	$	7,849,999.30	 

 

     

     

    

 

Exhibit B

 

Registration Rights Agreement

 

[To be attached]

 

     

     

    

 

Exhibit C

 

Significant Subsidiaries

 

	
        Entity
	
        Jurisdiction of Organization

	 	 
	Bankers Financial Products Corporation	Wisconsin
	The Deal L.L.C.	Delaware
	Management Diagnostics Limited	United Kingdom

 

     

     

    

 

Disclosure Schedules

 

These are the “Disclosure
Schedules” referred to in the Securities Purchase Agreement dated as of November 10, 2017 (the “Agreement”)
among TheStreet, Inc., a Delaware corporation, and each of the Persons listed as an Investor on the Schedule of Investors attached
as Schedule I thereto. Capitalized terms used but not defined herein have the meanings assigned to them in the Agreement.

 

Schedule 4.1     Organization, Good
Standing and Qualification.

 

		1.	Subsidiaries of the Company:

 

	
        Entity
	
        Jurisdiction of Organization

	 	 
	Bankers Financial Products Corporation	Wisconsin
	BankingMyWay.com, LLC	Wisconsin
	Boardex LLC	Delaware
	Management Diagnostics Limited	United Kingdom
	MDL ESOP Limited	United Kingdom
	SP-TSC Holdings LLC	Delaware
	Stockpickr LLC	Delaware
	The Deal L.L.C.	Delaware

Schedule 4.3      Capitalization.

 

		1.	Authorized and outstanding capital stock:

 

As of November 10, 2017, and without giving
effect to the transactions contemplated hereby or the TCV Exchange, the Company had:

		●	preferred stock; $0.01 par value; 10,000,000 shares authorized; 5,500 shares issued and outstanding
and designated Series B Preferred Stock;

		●	common stock; $0.01 par value; 100,000,000 shares authorized; 43,411,044 shares issued and 35,877,562
shares outstanding;

		●	treasury stock; at cost; 7,533,482 shares;

		●	1,168,013 shares of common stock available for future issuance under the Company’s 2007 Plan;

		●	5,383,261 shares of common stock issuable upon exercise of outstanding options;

		●	763,067 shares of common stock issuable upon vesting of granted restricted stock units;

 

    DS-1

    

 

		●	3,856,942 shares of common stock issuable upon conversion of the Series B Preferred Stock;

 

2.           The transactions contemplated by the following:

 

a.            TCV Agreement.

 

b.            Employment Agreement dated as of November 8, 2017, between James J. Cramer and the Company (the “Cramer Employment
Agreement”).

 

3.           Agreements with securityholders:

 

a.            TCV Agreement.

 

b.            Cramer Employment Agreement.

 

4.           Agreements with registration rights:

 

a.            TCV Agreement.

 

Schedule 4.8         No Material Adverse Change.

 

1.           The transactions contemplated by the following:

 

a.            TCV Agreement.

 

b.            Cramer Employment Agreement.

 

Schedule 4.14       Labor Matters.

 

1.           The following agreements:

 

a.            Cramer Employment Agreement.

 

Schedule 4.19       Brokers and Finders.

 

1.           The following agreements:

 

a.            Letter Agreement, dated September 11, 2017, between TheStreet, Inc. and Lake Street Capital Markets, LLC.

 

b.            Letter Agreement, dated November 7, 2017, between TheStreet, Inc. and B. Riley FBR, Inc.

 

Schedule 4.21       Transactions with Affiliates.

 

1.           The transactions contemplated by the following:

 

a.            Cramer Employment Agreement.

 

    DS-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00276-of-00352.parquet"}]]